var title_f15_59_16304="AVM pretreatment angiography";
var content_f15_59_16304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic angiographic appearance of an arteriovenous malformation before therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16304=[""].join("\n");
var outline_f15_59_16304=null;
var title_f15_59_16305="KS yellow perilesional halo";
var content_f15_59_16305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesion in a patient with AIDS-related Kaposi's sarcoma with a yellow perilesional halo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16305=[""].join("\n");
var outline_f15_59_16305=null;
var title_f15_59_16306="Min displaced tuberosity fracture";
var content_f15_59_16306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced tuberosity avulsion fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fracture (white arrow) extends into the joint between the cuboid and the fifth metatarsal but does not involve the intermetatarsal joint. Such fractures generally heal well with conservative management. Note the presence of an accessory ossicle (black arrowhead) just lateral to the proximal portion of the cuboid. Like most accessory ossicles, it is rounded, corticated, and located far from the fifth metatarsal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Eiff MP, Hatch RL, Calmbach W. Fracture Management for Primary Care, 2nd ed, W.B. Saunders, Philadelphia 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16306=[""].join("\n");
var outline_f15_59_16306=null;
var title_f15_59_16307="CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ";
var content_f15_59_16307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Axial CT section.",
"    <br>",
"     (B) Coronal maximal intensity projection (MIP) image shows a pure ground-glass nodule in the left lower lobe. Vessels and lung architecture are seen through the nodule.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16307=[""].join("\n");
var outline_f15_59_16307=null;
var title_f15_59_16308="Mahaim tachy RF ablation";
var content_f15_59_16308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ablation of Mahaim fiber tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel shows surface leads I and V1 and intracardiac recordings from the right ventricular apex (RVA), His-bundle (HBE), and a mapping catheter (MaP) located at the tricuspid annulus. A Mahaim potential (M) is seen in the MaP recording, located between the atrial (A) and ventricular (V) electrogram. In bottom panel, radiofrequency current is applied at the site of the M potential, resulting in loss of Mahaim conduction and termination of the tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16308=[""].join("\n");
var outline_f15_59_16308=null;
var title_f15_59_16309="Trans fx medial sesamoid A";
var content_f15_59_16309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74397%7EEM%2F52221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74397%7EEM%2F52221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the medial sesamoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In contrast to a bipartite sesamoid, the fracture line (white arrow) is relatively straight, and the corners of the fragments are more abrupt and less rounded. The fracture borders are also less distinct than the adjacent edges of the partite sesamoid and lack a rim of cortication. Lack of cortication is easier to appreciate on the lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the medial sesamoid (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16309=[""].join("\n");
var outline_f15_59_16309=null;
var title_f15_59_16310="Small cell carcinoma prostate";
var content_f15_59_16310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Small cell (neuroendocrine) carcinoma of the prostate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: high power photomicrograph of an hematoxylin and eosin stained tissue section of the prostate gland showing a small cell cancer. In contrast to prostate adenocarcinoma (a Gleason grade 4 adenocarcinoma is pictured in the right panel for comparison), small cell carcinoma of the prostate is composed of small tumor cells with neuroendocrine differentiation, and the absence of glandular structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16310=[""].join("\n");
var outline_f15_59_16310=null;
var title_f15_59_16311="The VIPoma syndrome";
var content_f15_59_16311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The VIPoma syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16311/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16311/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/59/16311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIPomas are rare neuroendocrine tumors that secrete vasoactive intestinal polypeptide (VIP). They are detected in 1 in 10 million people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of VIPomas arise within the pancreas, and are classified as a pancreatic neuroendocrine (islet cell) tumor along with insulinoma, glucagonoma, somatostatinoma, and gastrinoma. However, other VIP-secreting tumors have been reported, including bronchogenic carcinoma, colon carcinoma, ganglioneuroblastoma, pheochromocytoma, hepatoma, and adrenal tumors. In children, VIPomas occur in sympathetic ganglia and in the adrenal glands [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145093#H12145093\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Classification and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic pancreatic VIPomas are usually solitary, more than 3 cm in diameter, and occur in the tail of pancreas in 75 percent of patients. Approximately 60 to 80 percent of VIPomas have metastasized by the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VIPomas usually occur as isolated tumors, but are part of the multiple endocrine neoplasia syndrome type 1 (MEN1) in 5 percent of patients. The latter patients may also have primary hyperparathyroidism, pituitary tumors, gastrinoma, and other tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .) In one report of 580 patients with the MEN-1 syndrome, only 2 (0.65 percent) harbored a VIPoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoactive intestinal polypeptide (VIP)is a 28 amino acid polypeptide that binds to high affinity receptors on intestinal epithelial cells, leading to activation of cellular adenylate cyclase and cAMP production. This results in net fluid and electrolyte secretion into the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. VIP also has other actions that may be clinically important in patients with a VIPoma (",
"    <a class=\"graphic graphic_table graphicRef52546 \" href=\"UTD.htm?15/63/16379\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38406?source=see_link\">",
"     \"Vasoactive intestinal polypeptide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The VIPoma syndrome is caused by excessive, unregulated secretion of VIP by the tumor. However, other substances, such as prostaglandin E2, may occasionally be secreted by the tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adults with VIPomas are between the ages of 30 and 50 years and most children are between the ages of two and four years. The majority of patients have the VIPoma syndrome, also called the pancreatic cholera syndrome, Verner-Morrison syndrome, and the watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria (WDHA) syndrome. As indicated by the last name, the main findings are watery diarrhea, hypokalemia, and hypochlorhydria (since vasoactive intestinal polypeptide [VIP] suppresses gastric acid secretion). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The stool volume exceeds 700",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in all patients (even during fasting) and 3000",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The stools are tea-colored, odorless, with features of a secretory diarrhea such as persistence with fasting, high sodium concentration and, as described below, a low stool osmolal gap. Abdominal pain is mild or absent.",
"   </p>",
"   <p>",
"    Associated symptoms include flushing episodes in 20 percent of patients and symptoms related to hypokalemia and dehydration, such as lethargy, nausea, vomiting, muscle weakness, and muscle cramps. Flushing episodes are attributable to the vasodilator action of VIP.",
"   </p>",
"   <p>",
"    Hypochlorhydria occurs in 75 percent of patients. Other common findings are hyperglycemia and hypercalcemia (",
"    <a class=\"graphic graphic_table graphicRef52546 \" href=\"UTD.htm?15/63/16379\">",
"     table 1",
"    </a>",
"    ). The latter may be due to coexistent hyperparathyroidism as part of the MEN1 syndrome or to hyperalbuminemia caused by dehydration. In this situation, the serum total calcium concentration is increased but the serum free ionized calcium concentration may be normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS, TUMOR LOCALIZATION, AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two steps involved in the diagnosis of any of the pancreatic neuroendocrine tumors: identifying the presence of hypersecretion of the relevant hormone, and localizing the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H390935\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a VIPoma is established by the presence of an otherwise unexplained high volume secretory diarrhea and a serum vasoactive intestinal polypeptide (VIP) concentration in excess of 75",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    A single elevated VIP level should be confirmed by additional testing. VIP levels are measured by radioimmunoassay.",
"   </p>",
"   <p>",
"    The presence of a secretory diarrhea is supported by identifying a low osmotic gap in a fresh or refrigerated watery stool specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/10\">",
"     10",
"    </a>",
"    ]. The osmotic gap is determined by subtracting the sum of the sodium and potassium concentration in stool multiplied by a factor of 2 from 290",
"    <span class=\"nowrap\">",
"     mOsm/kg",
"    </span>",
"    to account for unmeasured anions (ie, 290 - 2 ({Na+} + {K+})) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/42/9890?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). An osmotic gap of &gt;125",
"    <span class=\"nowrap\">",
"     mOsm/kg",
"    </span>",
"    suggests an osmotic diarrhea while a gap of &lt;50",
"    <span class=\"nowrap\">",
"     mOsm/kg",
"    </span>",
"    suggests a secretory diarrhea. Among the other disorders that can cause a secretory diarrhea are surreptitious abuse of non-saline cathartics, enteritis caused by enterotoxigenic Escherichia coli or Vibrio cholera, collagenous or lymphocytic colitis, bile salt malabsorption due to ileal resection, and the carcinoid syndrome (",
"    <a class=\"graphic graphic_table graphicRef65916 \" href=\"UTD.htm?8/6/8299\">",
"     table 2",
"    </a>",
"    ). The AGA guideline for the evaluation and management of chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/11\">",
"     11",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    An elevated osmotic gap is present if the measured stool osmolality (determined by the laboratory) significantly exceeds the calculated value. An osmotic gap indicates the presence of an unmeasured solute, which can be due to saline laxatives containing magnesium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , lactose, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    as the active ingredients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391020\">",
"    <span class=\"h2\">",
"     Localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most pancreatic VIPomas are more than 3 cm in size at presentation, a pancreatic mass can usually be identified by computed tomography (CT) in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/12\">",
"     12",
"    </a>",
"    ]. Helical, contrast-enhanced triple phase CT is preferred. Intravenous contrast enhances the detection of smaller lesions, especially when images are obtained during the arterial phase. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared to the surrounding normal liver parenchyma.",
"   </p>",
"   <p>",
"    As a result of its greater sensitivity for liver metastases, some physicians prefer MRI over CT for assessing the status of the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145114#H12145114\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If cross sectional imaging is inconclusive, endoscopic ultrasound (EUS) or somatostatin receptor scintigraphy using radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    may be used to identify the tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS can detect pancreatic tumors as small as 2 to 3 mm, provides accurate information on the local extent of disease, and allows transmucosal needle biopsy of pancreatic lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somatostatin receptor scintigraphy (SRS) using radiolabeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      is very sensitive for pancreatic neuroendocrine tumors, including VIPomas [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/13\">",
"       13",
"      </a>",
"      ]. However, technological advancements in CT and MRI over the past several decades have led to diminished utility of SRS as a component of the staging workup for pancreatic neuroendocrine tumors, particularly for VIPomas, which are usually large by the time of diagnosis, and easily visualized on cross sectional imaging.",
"      <br/>",
"      <br/>",
"      SRS can identify clinically unsuspected extraabdominal metastases, and there may still be a role for SRS in the evaluation of a patient with VIPoma if the finding of extraabdominal metastases would change patient management and the treatment plan. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145128#H12145128\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic endocrine tumors such as VIPomas are included in the combined American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) TNM (tumor-node-metastasis) staging system for pancreatic tumors (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/14\">",
"     14",
"    </a>",
"    ]. Five- and ten-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors (both pancreatic neuroendocrine and carcinoid tumors) stratified by stage at presentation are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef80523 \" href=\"UTD.htm?4/42/4780\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of a patient with a VIPoma begins with replacement of fluid losses and correction of electrolyte abnormalities. Many patients require more than 5 L of fluid and 350 mEq of potassium daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Octreotide and lanreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    (a somatostatin analogue) decreases vasoactive intestinal polypeptide (VIP) secretion and is the treatment of choice to control diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The usual dose is 50 to 100 micrograms subcutaneously every eight hours. The availability of a once monthly depot form of octreotide (Sandostatin LAR&reg;) has largely eliminated the need for patients to inject themselves daily. Long-acting octreotide is typically initiated at a dose of 20 mg IM after a brief trial of the short-acting formulation, with gradual escalation of the dose as needed for optimal control of symptoms.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     Lanreotide",
"    </a>",
"    , another somatostatin analog, which is available internationally but not in the United States, appears to have similar clinical efficacy as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and is also available in a long-acting depot form (Lanreotide-SR).",
"   </p>",
"   <p>",
"    Somatostatin analogs are usually well tolerated, but there are some side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. About one-third of patients have nausea, abdominal discomfort, bloating, loose stools and fat malabsorption during the first several weeks of therapy, after which the symptoms subside. Mild glucose intolerance rarely occurs, due to transient inhibition of insulin secretion. More importantly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    reduces postprandial gallbladder contractility and delays gallbladder emptying, and up to 25 percent of patients develop asymptomatic cholesterol gallstones or sludge during the first 18 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although somatostatin analogs are highly effective at controlling the symptoms of hormone hypersecretion, they are of uncertain benefit for asymptomatic patients; objective evidence of antitumor activity has not been clearly shown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa (IFNa) improves symptoms of hormonal hypersecretion in 40 to 50 percent of patients with pancreatic neuroendocrine tumors. Furthermore, it induces tumor stabilization in 20 to 40 percent, and objective tumor regression in about 15 percent of patients. Widespread acceptance of IFNa for treatment of metastatic pancreatic neuroendocrine tumors has been limited by studies challenging its antitumor efficacy, and the potential for side effects, which may include disabling fatigue, depression, alteration of thyroid function, and myelosuppression.",
"   </p>",
"   <p>",
"    The addition of IFNa to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    may control symptoms in patients who are resistant or refractory to octreotide alone (",
"    <a class=\"graphic graphic_table graphicRef52546 \" href=\"UTD.htm?15/63/16379\">",
"     table 1",
"    </a>",
"    ). However, it is not clear that combined therapy is superior to either agent alone for initial therapy in terms of symptom control, objective antitumor response, or survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948949#H190948949\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients who are refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    may also respond to combined therapy with a glucocorticoid plus octreotide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Liver-directed therapy for metastatic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, symptoms of hormone hypersecretion are effectively palliated, and prolonged survival is often possible given the slow-growing nature of these tumors.",
"   </p>",
"   <p>",
"    As a general rule, resection should be undertaken only in patients with a limited number of hepatic metastases and is most successful when undertaken with curative intent. Concomitant resection of the primary is indicated if the primary site is causing symptoms, or if both the primary site and liver metastases are amenable to potentially curative resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative complications include rebound gastric acid hypersecretion and intravascular fluid overload resulting from a shift of copious amounts of fluid from the intestinal lumen. Proton pump inhibitors and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    are recommended in the preoperative and perioperative period to prevent these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hepatic artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver metastases derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive most of their blood supply from the portal vein. This provides the rationale for therapeutic embolization of the hepatic artery, with the goal of inducing necrosis of the metastases with minimal damage to normal liver parenchyma.",
"   </p>",
"   <p>",
"    Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     RFA and cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches to the treatment of hepatic-predominant disease include radiofrequency ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/21\">",
"     21",
"    </a>",
"    ]. These procedures, which can be performed using percutaneous or laparoscopic approaches, appear to be less invasive than either hepatic resection or hepatic artery embolization. However, both techniques are applicable only to smaller lesions and their long-term efficacy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691456#H691456\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'RFA and cryoablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation (OLT) has been attempted is small and follow-up data are insufficient to judge whether complete cure has truly been achieved. The limited availability of donor organs in many regions has restricted investigation of this procedure. Until more data become available, most clinicians consider liver transplantation an investigational approach for metastatic pancreatic neuroendocrine tumors, including VIPoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691420#H691420\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy and novel treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with systemic chemotherapy is limited. The traditional regimen of choice has been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Although objective response rates as high as 69 percent were initially reported for metastatic islet cell tumors, with decreases in endocrine hyperfunction, the true radiologic response rate is probably between 10 and 40 percent. Few patients with VIPoma have been included in reported chemotherapy series. Uncertainty as to efficacy, as well as the toxicity of this regimen, which can include nausea, prolonged myelosuppression, and renal failure, has prevented the widespread acceptance of chemotherapy as a standard first-line therapy for patients with metastatic pancreatic neuroendocrine tumors.",
"   </p>",
"   <p>",
"    More recently, antitumor activity has also been shown for regimens containing the orally active alkylating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . In the absence of comparative trials, the choice of first-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"      streptozocin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"    </span>",
"    or a temozolomide-based regimen must be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948956#H190948956\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest efficacy of conventional cytotoxic chemotherapy has prompted the development of novel therapeutic approaches for patients with advanced islet cell tumors. In the United States, two molecularly targeted therapies were approved for treatment of advanced pancreatic neuroendocrine tumor in 2011:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , a small molecule multitargeted tyrosine kinase inhibitor, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , an inhibitor of the mammalian target of rapamycin (mTOR). These and other novel therapies, such as peptide receptor radioligand therapy with radiolabeled somatostatin analogs, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949119#H190949119\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Peptide receptor radioligand therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949026#H190949026\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Molecularly targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from which to make recommendations for follow-up after resection of a VIPoma. Guidelines from the National Comprehensive Cancer Network based upon expert consensus include the following recommendations for follow-up after treatment of a pancreatic neuroendocrine tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16311/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three and six months postresection &ndash; History and physical examination, tumor markers, and",
"      <span class=\"nowrap\">",
"       CT/MRI.",
"      </span>",
"     </li>",
"     <li>",
"      Long-term &ndash; History and physical examination with serum VIP level every six to 12 months for years 1 to 3, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of patients with VIPomas is 103 months, the estimated five-year survival is 88 percent, and the 10-year survival is 25 percent. A favorable prognosis is associated with small tumors (&lt;4 cm), the absence of metastasis, and age (40 to 60 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VIPomas are rare neuroendocrine tumors that secrete vasoactive intestinal polypeptide (VIP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adults with VIPomas are between the ages of 30 and 50 years and most children are between the ages of 2 and 4 years. The majority of patients have the VIPoma syndrome, characterized by watery diarrhea, hypokalemia, and hypochlorhydria (since VIP suppresses gastric acid secretion). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two steps involved in the diagnosis of any of the pancreatic neuroendocrine tumors: identifying the presence of hypersecretion of the relevant hormone, and localizing the tumor.",
"      <br/>",
"      <br/>",
"      The diagnosis of VIPoma is established by the presence of an otherwise unexplained high volume secretory diarrhea and a serum VIP concentration in excess of 75",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"      A single elevated VIP level should be confirmed by additional testing. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis, tumor localization, and staging'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Cross sectional imaging with helical, triple-phase abdominal computed tomography (CT) is the initial imaging procedure of choice. Since the primary tumor is usually large by the time of diagnosis, it is localizable by CT in the majority of cases. As a result of its greater sensitivity for liver metastases, some physicians prefer magnetic resonance imaging (MRI) over CT for assessing the status of the liver. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link&amp;anchor=H11#H11\">",
"       \"Glucagonoma and the glucagonoma syndrome\", section on 'Cross sectional imaging'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endoscopic ultrasound (EUS)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      somatostatin receptor scintigraphy (SRS) may also be used when cross sectional imaging is unrevealing in a patient with suspected VIPoma. In addition, SRS may be indicated in the evaluation of a patient with VIPoma if the finding of extraabdominal metastases would change patient management and the treatment plan. (See",
"      <a class=\"local\" href=\"#H391020\">",
"       'Localization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of a patient with a VIPoma begins with replacement of fluid losses and correction of electrolyte abnormalities. For treatment of the diarrhea, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , given as described above (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) In patients who have diarrhea refractory to octreotide, we suggest standard interferon alfa, which can be given either as three million units daily or six million units three times a week (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Octreotide and lanreotide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic resection can be considered in patients with metastatic disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases. Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy may be used for palliation in patients with symptomatic hepatic metastases who are not candidates for surgical resection.",
"      <br/>",
"      <br/>",
"      Long-term efficacy of radiofrequency ablation and cryoablation are unknown and experience with orthotopic liver transplantation and chemotherapy are limited. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Liver-directed therapy for metastatic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Chemotherapy and novel treatment approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/1\">",
"      Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987; 67:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/2\">",
"      Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/3\">",
"      Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/4\">",
"      Lecorguill&eacute; M, Hammel P, Couvelard A, et al. [Jejunal vipoma]. Gastroenterol Clin Biol 2004; 28:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/5\">",
"      Meriney DK. Pathophysiology and management of VIPoma: a case study. Oncol Nurs Forum 1996; 23:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/6\">",
"      Bloom SR, Yiangou Y, Polak JM. Vasoactive intestinal peptide secreting tumors. Pathophysiological and clinical correlations. Ann N Y Acad Sci 1988; 527:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/7\">",
"      Krejs GJ. VIPoma syndrome. Am J Med 1987; 82:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/8\">",
"      Grier JF. WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 1995; 88:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/9\">",
"      Mekhjian HS, O'Dorisio TM. VIPoma syndrome. Semin Oncol 1987; 14:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/10\">",
"      Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/11\">",
"      American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/12\">",
"      Kirkwood KS, Debas HT. Neuroendocrine tumors: common presentations of uncommon diseases. Compr Ther 1995; 21:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/13\">",
"      Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52:1259.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/15\">",
"      Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/16\">",
"      Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/17\">",
"      O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/18\">",
"      Kraenzlin ME, Ch'ng JL, Wood SM, et al. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/19\">",
"      Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/20\">",
"      Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16311/abstract/21\">",
"      Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology 2006; 6:155.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2610 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16311=[""].join("\n");
var outline_f15_59_16311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS, TUMOR LOCALIZATION, AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H390935\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H391020\">",
"      Localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Octreotide and lanreotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Liver-directed therapy for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hepatic artery embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - RFA and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy and novel treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2610\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2610|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/63/16379\" title=\"table 1\">",
"      Pathophysiology of clinical manifestations of the VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/6/8299\" title=\"table 2\">",
"      Major causes of chronic secretory diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 3\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/42/4780\" title=\"table 4\">",
"      Survival rates following resection of a pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/42/9890?source=related_link\" title=\"calculator 1\">",
"      Calculator: Stool osmolal gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=related_link\">",
"      Physiology of gastric acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38406?source=related_link\">",
"      Vasoactive intestinal polypeptide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_59_16312="Definition and pathogenesis of chronic pain";
var content_f15_59_16312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and pathogenesis of chronic pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Howard S Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16312/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/59/16312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1732164\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is one of the most common and debilitating patient complaints, affecting individual patients, their friends and families, the work force, and society in general.",
"   </p>",
"   <p>",
"    Over 100 million Americans suffer chronic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/1\">",
"     1",
"    </a>",
"    ] and roughly 63 percent of pain sufferers seek help from their primary care clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/2\">",
"     2",
"    </a>",
"    ]. Pain accounts for 20 percent of outpatient visits and 12 percent of all prescriptions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with symptoms of chronic pain are seen by clinicians in multiple clinical settings. Most patients who present with pain complaints rate their symptoms as moderate to severe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent pain often causes functional impairment and disability, psychological distress (anxiety, depression), and sleep deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/6\">",
"     6",
"    </a>",
"    ]. Almost 80 percent of chronic pain patients report that pain disrupts their activities of daily living, and two-thirds indicate that pain has negatively impacted personal relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain is the most common cause of long-term disability, with lost work days in the United States estimated at more than 50 million days per year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/8\">",
"     8",
"    </a>",
"    ]. The annual cost of untreated or undertreated pain to taxpayers and employers has been calculated at over $100 billion per year, in direct and indirect expenses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/3\">",
"     3",
"    </a>",
"    ]. The use and misuse of opioids for management of chronic pain is a major concern, with problems arising from their multiple adverse side effects including drug-dependency, from drug diversion, and from undertreatment of chronic pain symptoms for fear of narcotic abuse. Chronic pain is thus a major medical and social issue.",
"   </p>",
"   <p>",
"    Research efforts in understanding pain range from the molecular biology of nociceptive pathways to the psychosocial aspects that influence the experience of pain. Although such studies have resulted in significant strides in pain management and quality of life for patients with persistent pain, the evaluation and treatment of pain remains suboptimal.",
"   </p>",
"   <p>",
"    An overview of the definition, classification, and pathogenesis of chronic pain is presented here. The evaluation of patients presenting with chronic pain, the general therapeutical principles of chronic pain, and specific pain syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732172\">",
"    <span class=\"h1\">",
"     PAIN-RELATED DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pain is a vital, protective mechanism that permits us to live in an environment fraught with potential dangers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ]. Certain stimuli are associated with danger that should be avoided, even at some cost, to prevent tissue damage.",
"   </p>",
"   <p>",
"    Pain can be considered in two broad categories: adaptive and maladaptive. Adaptive pain contributes to survival by protecting the organism from injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    promoting healing when injury has occurred. Maladaptive or chronic pain is pain as disease and represents pathologic functioning of the nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732180\">",
"    <span class=\"h2\">",
"     Pain definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain has been variously defined. A commonly used definition describes pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/10\">",
"     10",
"    </a>",
"    ]. A revised definition identifies pain as \"a somatic perception containing: (1) a bodily sensation with qualities like those reported during tissue-damaging stimulation, (2) an experienced threat associated with this sensation, and (3) a feeling of unpleasantness or other negative emotion based on this experienced threat\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732188\">",
"    <span class=\"h2\">",
"     Chronic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain has been defined as pain which lasts beyond the ordinary duration of time that an insult or injury to the body needs to heal. An argument has been made that the term \"persistent pain\" should be used in lieu of \"chronic pain\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative definitions are based on a specified duration of pain, although there is discrepancy on what that duration should be.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Association for the Study of Pain (IASP) definition addresses both duration and appropriateness, defining chronic pain as pain without apparent biologic value that has persisted beyond the normal tissue healing time (usually taken to be three months) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Rheumatology (ACR) defines chronic pain as widespread or regional pain for at least three months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/14\">",
"       14",
"      </a>",
"      ]. ACR criteria for chronic widespread pain include all of the following: pain present for at least three months, pain in the left and right sides of the body, pain above and below the waist, and the presence of axial skeletal pain (cervical spine anterior chest, thoracic spine, or low back).",
"     </li>",
"     <li>",
"      The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) defines chronic pain as persistent pain for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Society of Anesthesiologists defines chronic pain as pain of any etiology not directly related to neoplastic involvement &hellip; extending in duration beyond the expected temporal boundary of tissue injury and normal healing and adversely affecting the function or well-being of the individual [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain duration shorter than six months but present beyond the \"expected healing period\" has been termed \"subacute pain\" by some clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732195\">",
"    <span class=\"h2\">",
"     Pain descriptor terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following terms are commonly used descriptors of altered sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hyperalgesia",
"      </strong>",
"      &mdash; Increased response to a stimulus that normally is painful.",
"     </li>",
"     <li>",
"      <strong>",
"       Hypoalgesia &mdash;",
"      </strong>",
"      Diminished response to a normally painful stimulus.",
"     </li>",
"     <li>",
"      <strong>",
"       Analgesia",
"      </strong>",
"      &mdash; Absence of pain in response to stimulation that normally is painful.",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperesthesia",
"      </strong>",
"      &mdash; Increased sensitivity to stimulation, excluding the special senses.",
"     </li>",
"     <li>",
"      <strong>",
"       Hypesthesia",
"      </strong>",
"      &mdash; Diminished sensitivity to stimulation, excluding the special senses.",
"     </li>",
"     <li>",
"      <strong>",
"       Dysesthesia",
"      </strong>",
"      &mdash; An unpleasant abnormal sensation, whether spontaneous or evoked.",
"     </li>",
"     <li>",
"      <strong>",
"       Paresthesia",
"      </strong>",
"      &mdash; An abnormal sensation, whether spontaneous or evoked.",
"     </li>",
"     <li>",
"      <strong>",
"       Allodynia &mdash;",
"      </strong>",
"      Pain resulting from a stimulus (such as light touch) that does not normally elicit pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732203\">",
"    <span class=\"h2\">",
"     Types of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is often categorized as being either nociceptive or neuropathic. Other pain schemes define additional categories (psychogenic or muscle pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The primary distinction between nociceptive and neuropathic pain has implications for evaluation and treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732211\">",
"    <span class=\"h3\">",
"     Nociceptive pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nociceptor is a nerve fiber preferentially sensitive to a noxious stimulus or to a stimulus that would become noxious if prolonged. Nociceptive pain is the perception of nociceptive input, usually due to tissue damage (eg, postoperative pain). Nociceptive pain is further subdivided into somatic and visceral pain. Somatic pain arises from injury to body tissues. It is well localized but variable in description and experience. Visceral pain is pain arising from the viscera mediated by stretch receptors. It is poorly localized, deep, dull, and cramping (eg, pain associated with appendicitis, cholecystitis, or pleurisy).",
"   </p>",
"   <p>",
"    One classification system of pain further subdivides nociceptive pain as musculoskeletal pain, inflammatory pain (eg, inflammatory arthropathies, postoperative pain, tissue injury, infection), or",
"    <span class=\"nowrap\">",
"     mechanical/compressive",
"    </span>",
"    pain (eg, low back pain, neck pain, visceral pain from expanding tumor masses) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732225\">",
"    <span class=\"h3\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system. It commonly persists without ongoing disease (eg, diabetic neuropathy, trigeminal neuralgia, or thalamic pain syndrome). Neuropathic pain is further subdivided as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sympathetically mediated pain (SMP) is pain arising from a peripheral nerve lesion and associated with autonomic changes (eg, complex regional pain syndrome I and II, formerly known as reflex sympathetic dystrophy and causalgia) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral neuropathic pain is due to damage to a peripheral nerve without autonomic change (eg, postherpetic neuralgia, neuroma formation).",
"     </li>",
"     <li>",
"      Central pain arises from abnormal central nervous system (CNS) activity (eg, phantom limb pain, pain from spinal cord injuries, and post-stroke pain).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neuropathy is also described as mononeuropathy if one nerve is affected, mononeuropathy multiplex if several nerves in different areas of the body are involved, and polyneuropathy if symptoms are diffuse and bilateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732232\">",
"    <span class=\"h2\">",
"     Pain taxonomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Association for the Study of Pain (IASP) has developed a taxonomy for the classification of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/10\">",
"     10",
"    </a>",
"    ]. This classification system identifies five axes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Axis I: Anatomic regions",
"     </li>",
"     <li>",
"      Axis II: Organ systems",
"     </li>",
"     <li>",
"      Axis III: Temporal characteristics, pattern of occurrence",
"     </li>",
"     <li>",
"      Axis IV: Intensity, time since onset of pain",
"     </li>",
"     <li>",
"      Axis V: Etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The IASP Classification of Chronic Pain is compatible with the International Classification of Diseases (ICD 9 and ICD 10) but provides for more detailed identification of various chronic pain syndromes and major acute pain syndromes.",
"   </p>",
"   <p>",
"    Simpler schemes often are used in the day to day practice of pain medicine.",
"    <strong>",
"    </strong>",
"    One scheme identifies eight unidimensional subtypes or classifications for pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain location (eg, low back pain, headache)",
"     </li>",
"     <li>",
"      Pain duration (eg acute, subacute, chronic) (see",
"      <a class=\"local\" href=\"#H1732188\">",
"       'Chronic pain'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pain origin (eg nociceptive or neuropathic) (see",
"      <a class=\"local\" href=\"#H1732203\">",
"       'Types of pain'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Diagnosis (eg, cancer pain, sickle cell pain, postherpetic neuralgia) (see",
"      <a class=\"local\" href=\"#H1732256\">",
"       'Pathogenesis of pain'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Body system (eg, myofascial, rheumatic, neurologic, vascular) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pain severity (eg, mild, moderate, or severe)",
"     </li>",
"     <li>",
"      Pain mechanism(s) (eg, peripheral sensitization, disinhibition, or central sensitization) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/24\">",
"       24",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H1732280\">",
"       'Mechanisms for persistent pain'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Treatment responsiveness (eg, opioid-responsive pain, opioid poorly responsive pain)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two of these classifications may be combined (eg, chronic noncancer pain).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732256\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain sensation begins in the periphery of the nervous system. Pain stimuli are sensed by specialized nociceptors that are the nerve terminals of the primary afferent fibers. The pain signal is then transmitted to the dorsal horn of the spinal column and transmitted through the central nervous system (CNS) where it is processed and interpreted in the somatosensory cerebral cortex (",
"    <a class=\"graphic graphic_figure graphicRef64245 \" href=\"UTD.htm?23/0/23557\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple ascending pathways may be involved in relaying nociceptive information to the brain, including spinocervical, spinobulbar, spinopontine, spinomesencephalic, spino-diencephalic (containing spinothalamic tracts), and spinotelencephalic pathways. The majority of the wide dynamic range and nociceptive specific neurons project contralaterally within the spinal cord and ascend within the anterolateral quadrant, forming the spinothalamic tract which synapses in the thalamus (",
"    <a class=\"graphic graphic_figure graphicRef52893 \" href=\"UTD.htm?9/48/9989\">",
"     figure 2",
"    </a>",
"    ). Neurons from the thalamus project to multiple brain areas in the primary and secondary somatosensory cortex, cingulate cortex, prefrontal cortex, insular cortex, amygdala, and the cerebellum.",
"   </p>",
"   <p>",
"    Four physiologic processes are associated with pain: transduction, transmission, modulation, and perception.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Transduction",
"      </strong>",
"      refers to the conversion of a noxious stimulus (thermal, mechanical, or chemical) into electrical activity in the peripheral terminals of nociceptor sensory fibers.",
"     </li>",
"     <li>",
"      <strong>",
"       Transmission",
"      </strong>",
"      refers to the passage of action potentials from the peripheral terminal along axons to the central terminal of nociceptors in the central nervous system. Conduction is the synaptic transfer of input from one neuron to another.",
"     </li>",
"     <li>",
"      <strong>",
"       Modulation",
"      </strong>",
"      refers to the alteration (eg, augmentation or suppression) of sensory input.",
"     </li>",
"     <li>",
"      <strong>",
"       Perception",
"      </strong>",
"      refers to the",
"      <span class=\"nowrap\">",
"       \"decoding\"/interpretation",
"      </span>",
"      of afferent input in the brain that gives rise to the individual's specific sensory experience.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732264\">",
"    <span class=\"h2\">",
"     Nociceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nociceptors are a highly-specialized subset of primary sensory neurons that respond only to pain stimuli. They are categorized by the kind of stimulation they respond to and the nature of their response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/25\">",
"     25",
"    </a>",
"    ]. Most noxious stimuli activate a variety of nociceptor types in the affected area. Their signals sum to produce the nociceptive input, leading to the subjective sense of pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myelinated nociceptors are relatively fast-conducting A-delta fibers. Some respond readily to heat (mechanothermal receptors, MTRs); others are high-threshold mechanoreceptors (HTMs). The discharge intensity is linearly related to the degree of the stimulus [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/26\">",
"       26",
"      </a>",
"      ]. A-delta fibers are responsible for the first (immediate) sharp pain.",
"     </li>",
"     <li>",
"      Unmyelinated C fibers constitute the large majority of peripheral nociceptors. Most are classified as C-polymodal nociceptors (C-PMN), responding to thermal, mechanical, and chemical stimuli. These are slow-conducting primary afferents that recover from fatigue more slowly than those of A-delta nociceptors. C fibers mediate delayed and longer-lasting pain, typically characterized as dull.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nociceptors also vary in their threshold to response and their rate of firing to the dorsal horn of the spinal cord. Wide dynamic range (WDR) nociceptors respond to a continuum of stimuli, such as moderate warmth through noxious high temperatures. Other nociceptors respond only to noxious stimuli (nociceptor specific, NS).",
"   </p>",
"   <p>",
"    Nociceptive afferents are classified as peptidergic or nonpeptidergic. Peptidergic cells express substance P,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcitonin gene-related peptide or somatostatin as well as tyrosine kinase receptor A",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    TRPV1 and project centrally to lamina I and the outer lamina II of the dorsal horn. Nonpeptidergic cells express the purinergic ligand-gated ion channel P2X3 and project centrally to the inner lamina II of the dorsal horn.",
"   </p>",
"   <p>",
"    Sodium channel subunits in the cell membrane of nociceptive neurons control the generation of nerve impulses that travel from dorsal root ganglia to the brain. Genes have been identified which code differing protein isoforms of the sodium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/27\">",
"     27",
"    </a>",
"    ]. One of these genes, SCN9A, encodes a specific sodium channel (Na(v)1,7) that is found in nociceptive and sympathetic ganglion neurons, and appears to modulate the pain signal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/28\">",
"     28",
"    </a>",
"    ]. This finding suggests an intriguing opportunity to develop pharmacologic agents, targeted to the Na(v)1,7 sodium channel, which might inhibit pain sensation with minimal other physiologic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732272\">",
"    <span class=\"h2\">",
"     CNS processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal transfer from nociceptors to neurons in the dorsal horn of the spinal cord that project to the brain is mediated either by direct monosynaptic contact or through interneurons, which may be either excitatory or inhibitory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ]. Counterirritation and low-threshold afferent inputs (transcutaneous electrical nerve stimulation or spinal cord stimulation), used to modulate pain in patients with chronic pain syndromes, activate inhibitory mechanisms but their effect is generally small and short lasting.",
"   </p>",
"   <p>",
"    A small fraction of the sensory input that enters the spinal cord is transmitted via action potentials from the neurons in the dorsal horn to the thalamus. The thalamus relays this information to the cortex.",
"   </p>",
"   <p>",
"    Sensory processing is controlled through local segmental circuits in the spinal cord and by descending inhibitory and facilitatory signals arising from the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ]. The CNS is equipped with a descending or modulatory system which acts to alter afferent nociceptive information. Several regions of the brain are involved in this activity, including the somatosensory cortex, the hypothalamus, the periaqueductal gray matter, and areas in the pons. Prefrontal cortex and anterior cingulate cortex circuitry may also dampen nociceptive input and cause analgesia. Descending fibers from these structures pass through the dorsolateral funiculus (DLF) and synapse with nociceptive neurons in the dorsal horn of the spinal cord. These fibers may interact with the opioid system, noradrenergic system, and serotonergic system, and can significantly inhibit responses to noxious stimuli. Additionally, descending facilitatory pain pathways are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732280\">",
"    <span class=\"h1\">",
"     MECHANISMS FOR PERSISTENT PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mechanisms promote or facilitate persistent or chronic pain. These include peripheral sensitization, central sensitization, ectopic excitability, structural",
"    <span class=\"nowrap\">",
"     reorganization/phenotypic",
"    </span>",
"    switch of neurons, primary sensory degeneration, and disinhibition. Peripheral and central sensitization are the major causes of pain hypersensitivity after injury.",
"   </p>",
"   <p>",
"    <strong>",
"     Peripheral sensitization &mdash;",
"    </strong>",
"    Tissue inflammation may result in changes in the chemical environment of the peripheral terminal of nociceptors. Damaged cells may release intracellular contents and synthesize substances including cytokines, chemokines, bradykinin, histamine, prostaglandins, and growth factors. Released cellular ions create a more acidic environment.",
"   </p>",
"   <p>",
"    Inflammatory cells are recruited to the site of damage, in part due to the attractant properties of proinflammatory mediators such as leukotriene B4 [LTB4] [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/29\">",
"     29",
"    </a>",
"    ]. Some of these proinflammatory mediators directly activate the nociceptor terminal and produce pain (nociceptor activators); others sensitize the terminal so that it becomes hypersensitive to subsequent stimuli (nociceptor sensitizers) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The release of adenosine triphosphatase by injured cells, for example, causes immediate activation and results in immediate detection of tissue damage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient receptor potential V1 (TRPV1) channels expressed by nociceptors may produce pain some time after injury [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/30\">",
"       30",
"      </a>",
"      ]. These channels are calcium-permeable nonelective cation channels gated by heat, low pH, or chemical mediators (&ldquo;endovanilloids&rdquo;). Activation of mitogen-activated protein kinase (MAPK) signaling in TRPV1 may contribute to hyperresponsiveness of peripheral nociceptors (peripheral sensitization). In addition to producing inflammation and inducing synthesis of several nociceptor sensitizers, IL-1beta also rapidly and directly activates nociceptors to generate action potentials and induce pain hypersensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732288\">",
"    <span class=\"h2\">",
"     Central sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central sensitization amplifies the synaptic transfer from the nociceptor terminal to dorsal horn neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ]. Initial sensitization to synaptic transfer is activity-dependent, triggered by nociceptor input into the spinal cord. Later transcriptional changes in the molecular machinery of the dorsal cell",
"    <strong>",
"    </strong>",
"    sustain the sensitization beyond the initiating stimulus (ie, transcription-dependent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Thus, previously subthreshold synaptic inputs to nociceptive neurons now generate an augmented action potential output.",
"   </p>",
"   <p>",
"    The glutamate-activated N-methyl-D-aspartic acid (NMDA) receptor is integral to this central sensitization process [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. During central sensitization, the NMDA receptor is phosphorylated, which increases its distribution in the synaptic membrane and its responsiveness to glutamate. Increased responsiveness to glutamate occurs by removal of a normal voltage-dependent magnesium ion block of the NMDA channel, increasing the time the channel is open. The increase in excitability of the dorsal horn cell means that it can be activated by normally subthreshold inputs, with increased response to suprathreshold inputs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimmune interaction resulting from the action of chemical signals produced by inflammatory cells on nerve fibers may contribute to peripheral and central sensitization. Transcription-dependent central sensitization has been studied in the context of peripheral inflammation where changes in brain derived neurotrophic factor (BDNF), substance P, neurokinin 1 (NK1), dynorphin and cyclooxygenase 2 (Cox 2) are well described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuron-glial interactions may also contribute to nociceptive processes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/38\">",
"     38",
"    </a>",
"    ]. The macrophage-like glial cells, quiescent in the normal spinal cord, are rapidly activated after nerve injury. These cells are a likely source of cytokines and chemokines that then act on neurons and their supporting glia to alter patterns of gene transcription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732296\">",
"    <span class=\"h2\">",
"     Ectopic excitability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased excitability of injured and neighboring uninjured sensory neurons can generate pacemaker-like ectopic action potential discharges, resulting in sensory inflow independent of a peripheral stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These changes may manifest at the site of the injury, at a neuroma, or in the dorsal root ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/41\">",
"     41",
"    </a>",
"    ]. These ectopic signals arise due to multiple factors including upregulation of voltage gated sodium channels, channel subunits, or signal receptors in myelinated neurons; or downregulation of potassium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732304\">",
"    <span class=\"h2\">",
"     Structural reorganization/phenotypic switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve injury may result in an altered profile of sensory neurons.",
"    <strong>",
"    </strong>",
"    The central terminals of nociceptor sensory neurons terminate in the most superficial laminae of the dorsal horn in the spinal cord. In contrast, low threshold sensory fibers activated by touch, pressure, vibration, and normal ranges of movement of joints terminate in the deep laminae of the dorsal horn.",
"   </p>",
"   <p>",
"    Experiments in rodents have shown that physical rearrangement of this circuitry may occur after peripheral nerve injury, with new growth of the central terminals of the low-threshold afferents seen in the zone normally occupied exclusively by nociceptor terminals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/44\">",
"     44",
"    </a>",
"    ]. Additionally, after peripheral nerve injury, the neuromodulators brain-derived neurotrophic factor (BDNF) and substance P, normally expressed only in C-fibers, may begin to be expressed in large-diameter A fiber neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732312\">",
"    <span class=\"h2\">",
"     Primary sensory degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of neurons (normally a source of growth factors) and the resulting imbalance of sensory inflow may contribute to the abnormal sensations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"     9",
"    </a>",
"    ]. This paradoxical increase in pain perception with neurite dropout is not well understood. Conceivably, this may be related to changes in neurotrophic factors, compensatory local changes in the surrounding neurons or dorsal root",
"    <span class=\"nowrap\">",
"     ganglion/dorsal",
"    </span>",
"    horn of the spinal cord, changes in related glia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    changes in cortical interpretation of afferent input.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732320\">",
"    <span class=\"h2\">",
"     Disinhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in inhibition can have an effect similar to increased excitability. Pharmacologically blocking GABA or glycine-mediated inhibition produces a pattern of pain",
"    <strong>",
"    </strong>",
"    hypersensitivity similar to that of neuropathic pain, with prominent tactile allodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/47\">",
"     47",
"    </a>",
"    ]. GABA blockade recruits previously absent ABeta fiber inputs to lamina II cells,",
"    <strong>",
"    </strong>",
"    effectively uncovering a previously silent synaptic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Partial",
"    <strong>",
"    </strong>",
"    nerve injury also reduces inhibition in the superficial dorsal horn, with selective loss of GABAergic",
"    <strong>",
"    </strong>",
"    inhibitory synaptic currents due to apoptosis in GABAergic inhibitory interneurons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/49\">",
"     49",
"    </a>",
"    ]. One week after nerve injury that produces hypersensitivity to pain, neurons begin to undergo apoptosis in the dorsal horn. The apoptosis may be due to excessive glutamate release or failure of glutamate uptake, or result from cell death-inducing signals, such as release of tumor necrosis factor-alpha from activated microglia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732328\">",
"    <span class=\"h2\">",
"     Clinical implication of mechanism of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;When pain symptoms fail to respond to traditional treatment, conventional approaches may be supplemented by a mechanism-based approach in efforts to individually tailor targeted therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. A mechanism-based approach accounts for the observation that patients with one disease (eg, diabetic neuropathy) may have different symptoms due to different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/52\">",
"     52",
"    </a>",
"    ]. Data regarding the determination of the precise pain mechanism in a given patient, and the effectiveness of therapy targeted to the mechanism, are preliminary, but current knowledge provides a framework for future investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16312/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23746?source=see_link\">",
"       \"Patient information: Chronic pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732336\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adaptive pain protects an organism from injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      promotes healing when injury has occurred. Maladaptive or chronic pain, in contrast, represents pathologic operation of the nervous system. (See",
"      <a class=\"local\" href=\"#H1732172\">",
"       'Pain-related definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic pain can be defined either as pain that persists beyond the ordinary time that an insult or injury needs to heal or as pain that persists beyond a stated time interval. This time interval is often indicated as three months, though some have identified the window as six months. (See",
"      <a class=\"local\" href=\"#H1732188\">",
"       'Chronic pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain is commonly classified as nociceptive, originating in damaged tissues outside the nervous system (including somatic and visceral pain), or neuropathic, arising from abnormal neural activity. Neuropathic pain can be sympathetically medicated (eg, reflex sympathetic dystrophy), peripheral (eg, postherpetic neuralgia), or central (eg, phantom limb or poststroke pain). (See",
"      <a class=\"local\" href=\"#H1732203\">",
"       'Types of pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain stimuli are sensed by specialized nociceptors that are the nerve terminals of the primary afferent fibers. The pain signal is then transmitted to the dorsal horn of the spinal column and transmitted through the central nervous system (CNS) where it is processed and interpreted in the somatosensory cerebral cortex. (See",
"      <a class=\"local\" href=\"#H1732256\">",
"       'Pathogenesis of pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nociceptors are categorized as fast-conducting A-delta fibers (myelinated nerves that signal immediate sharp pain) and slow-conducting unmyelinated C polymodal fibers that convey delayed dull pain. Nociceptors vary in their response threshold and rate of firing to the dorsal horn of the spinal cord. Nerve impulses are controlled through sodium channel subunits. (See",
"      <a class=\"local\" href=\"#H1732264\">",
"       'Nociceptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signals from nociceptors are transmitted to the dorsal horn cells in the spinal cord and may travel either directly or through interneurons to the thalamus and then to the cerebral cortex. Interneurons, as well as descending signal arising from the brain, may be excitatory or inhibitory. Stimulation of some cortical and subcortical areas may cause analgesia. Three endogenous systems (opioid, noradrenergic, and serotonergic) are involved in the descending control of nociceptive information and inhibit pain perception as part of the fight-or-flight reaction. (See",
"      <a class=\"local\" href=\"#H1732272\">",
"       'CNS processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral and central sensitization are the major causes of hypersensitivity to pain after injury. Substances released by injured cells can be nociceptor sensitizers. Changes in the NMDA receptor can increase dorsal horn excitability, and activated glial cells may produce cytokines that alter patterns of gene transcription. Other mechanisms involve ectopic excitability of some sensory neurons, physical rearrangement of neurons terminating in the dorsal horn, and disinhibition by partial nerve injury. (See",
"      <a class=\"local\" href=\"#H1732280\">",
"       'Mechanisms for persistent pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Available at file://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     National Centers for Health Statistics. Chartbook on trends in the Health of Americans 2006. file://www.cdc.gov/nchs/data/hus/hus06.pdf (Accessed on April 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/3\">",
"      Alford DP, Liebschutz J, Chen IA, et al. Update in pain medicine. J Gen Intern Med 2008; 23:841.",
"     </a>",
"    </li>",
"    <li>",
"     Coda BA, Bonica JJ. General considerations of acute pain. In: Bonica's Management of Pain, 3rd ed, Loeser JD, Butler SH, Chapman CR.  (Eds), Lippincott Williams &amp; Wilkins, Baltimore 2001. p.222.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/5\">",
"      Hardt J, Jacobsen C, Goldberg J, et al. Prevalence of chronic pain in a representative sample in the United States. Pain Med 2008; 9:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/6\">",
"      Brookoff D. Chronic pain: 1. A new disease? Hosp Pract (Minneap) 2000; 35:45.",
"     </a>",
"    </li>",
"    <li>",
"     Vo, P, Marx, S, Penles, L. Health-related quality of life (HRQoL) among patients experiencing acute and chronic moderate-to-moderately-severe pain: results from a survey of 606 pain patients in the United States. Paper presented at: American Pain Society Annual Meeting; May 8-10, 2008; Tampa, Florida.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/8\">",
"      Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/9\">",
"      Woolf CJ, American College of Physicians, American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140:441.",
"     </a>",
"    </li>",
"    <li>",
"     Merskey H, Bogduk N. Classification of Chronic Pain, 2nd ed, IASP Press, Seattle 1994.",
"    </li>",
"    <li>",
"     Price DD. Psychological Mechanisms of Pain and Analgesia In Progress in Pain Research and Management, IASP Press, Seattle 1999. Vol 15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/12\">",
"      Adler RH. The term \"chronic\" with respect to pain should be dropped. Clin J Pain 2000; 16:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/13\">",
"      International Association for the Study of Pain. Classification of chronic pain. Pain 1986; 24:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/14\">",
"      Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33:160.",
"     </a>",
"    </li>",
"    <li>",
"     America Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed, America Psychiatric Association, Washington 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/16\">",
"      American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010; 112:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/17\">",
"      Portenoy RK. Mechanisms of clinical pain. Observations and speculations. Neurol Clin 1989; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     Institute for Clinical Systems Improvement. Assessment and Management of Chronic Pain. November 2009. Available at: www.icsi.org (Accessed on April 14, 2010).",
"    </li>",
"    <li>",
"     Institute for Clinical Systems Improvement. Health care guideline: Assessment and management of chronic pain. Fourth edition November 2009. file://www.icsi.org/pain__chronic__assessment_and_management_of_14399/pain__chronic__assessment_and_management_of__guideline_.html (Accessed on December 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/20\">",
"      Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/21\">",
"      Stanton-Hicks M, J&auml;nig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995; 63:127.",
"     </a>",
"    </li>",
"    <li>",
"     Smith HS. Pain Taxonomy. In: The Neurologic Basis for Pain, Pappagalo M (Ed), McGraw-Hill, New York 2005. p.289.",
"    </li>",
"    <li>",
"     Friction J. Medical evaluation of patients with chronic pain. In: Psychological Approaches to the Management of Pain, Barber J, Adrian C (Eds), Brunner Mazel, New York 1982. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/24\">",
"      Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain 1998; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/25\">",
"      McCleskey EW, Gold MS. Ion channels of nociception. Annu Rev Physiol 1999; 61:835.",
"     </a>",
"    </li>",
"    <li>",
"     Fields HL. Pain, McGraw-Hill Information Services Company, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/27\">",
"      Waxman SG. Neurobiology: a channel sets the gain on pain. Nature 2006; 444:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/28\">",
"      Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A 2010; 107:5148.",
"     </a>",
"    </li>",
"    <li>",
"     Levine JD, Reichling DB. Peripheral mechanisms of inflammatory pain. In: Textbook of Pain, Wall PD, Melzack R (Eds), Churchill Livingstone, Edinburgh 1999. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/30\">",
"      Waldmann R. Proton-gated cation channels--neuronal acid sensors in the central and peripheral nervous system. Adv Exp Med Biol 2001; 502:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/31\">",
"      Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors are interleukin-1beta sensors. J Neurosci 2008; 28:14062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/32\">",
"      Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/33\">",
"      Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003; 26:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/34\">",
"      Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/35\">",
"      Neumann S, Doubell TP, Leslie T, Woolf CJ. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 1996; 384:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/36\">",
"      Mannion RJ, Costigan M, Decosterd I, et al. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci U S A 1999; 96:9385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/37\">",
"      Ji RR, Befort K, Brenner GJ, Woolf CJ. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 2002; 22:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/38\">",
"      Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009; 10:23.",
"     </a>",
"    </li>",
"    <li>",
"     Devor M, Seltzer Z. Pathophysiology of damaged nerves in relation to chronic pain. In: Textbook of Pain, Wall PD, Melzack R (Eds), Churchill Livingstone, Edinburg 1999. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/40\">",
"      Liu CN, Devor M, Waxman SG, Kocsis JD. Subthreshold oscillations induced by spinal nerve injury in dissociated muscle and cutaneous afferents of mouse DRG. J Neurophysiol 2002; 87:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/41\">",
"      Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004; 74:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/42\">",
"      Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci U S A 1999; 96:7635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/43\">",
"      Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006; 109:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/44\">",
"      Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992; 355:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/45\">",
"      Noguchi K, Kawai Y, Fukuoka T, et al. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons. J Neurosci 1995; 15:7633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/46\">",
"      Fukuoka T, Kondo E, Dai Y, et al. Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J Neurosci 2001; 21:4891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/47\">",
"      Sivilotti L, Woolf CJ. The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol 1994; 72:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/48\">",
"      Baba H, Ji RR, Kohno T, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci 2003; 24:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/49\">",
"      Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002; 22:6724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/50\">",
"      Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999; Suppl 6:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/51\">",
"      Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001; 95:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/52\">",
"      Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16312/abstract/53\">",
"      Smith HS, Sang CN. The evolving nature of neuropathic pain: Individualizing treatment. Eur J Pain Suppl 2002; 6:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2762 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16312=[""].join("\n");
var outline_f15_59_16312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1732336\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1732164\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1732172\">",
"      PAIN-RELATED DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732180\">",
"      Pain definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732188\">",
"      Chronic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732195\">",
"      Pain descriptor terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732203\">",
"      Types of pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1732211\">",
"      - Nociceptive pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1732225\">",
"      - Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732232\">",
"      Pain taxonomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1732256\">",
"      PATHOGENESIS OF PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732264\">",
"      Nociceptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732272\">",
"      CNS processing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1732280\">",
"      MECHANISMS FOR PERSISTENT PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732288\">",
"      Central sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732296\">",
"      Ectopic excitability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732304\">",
"      Structural reorganization/phenotypic switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732312\">",
"      Primary sensory degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732320\">",
"      Disinhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1732328\">",
"      Clinical implication of mechanism of pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1732336\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2762|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/0/23557\" title=\"figure 1\">",
"      Nerve convergence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/48/9989\" title=\"figure 2\">",
"      Spinothalmic pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23746?source=related_link\">",
"      Patient information: Chronic pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_59_16313="Central bronchiectasis CT";
var content_f15_59_16313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64077%7EPULM%2F53471%7EPULM%2F78762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64077%7EPULM%2F53471%7EPULM%2F78762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central bronchiectasis in a patient with allergic bronchopulmonary aspergillosis. Multiple dilated third and fourth generation bronchi are seen. Smaller peripheral bronchi filled with mucus account for the branching linear opacities in the distal lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of the lungs in a patient with cystic fibrosis, demonstrating bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 292px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEkAVsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxSk6UtFACelBFLj2pQKAAUo6UYOM1PDGAhlkHyA4C/wB40ANiikkPyIxHrU32f+/LGg+uTUcsryf6w4UdFHAH4V6F4F+F2o67DFqGsSf2VorciRx+9mHoi/1oA4vStOn1K+js9JtJ9QvJDhY414/GvWPD3wkMOyfxjqATPTT7Egvn0du1ej6JY2Hh+zNp4dtFsrfGHlPMsnuzdefSrtpYvOuUBC55Zhz+FAFLSLTTtCt/I0LT7exXqJFXfIx92OTWnDHeXR3yM8gP8TnJP0q/bWcNuMt87+p/pU7ssYBZgo7CgCommxt80z7j1OBxVuO0gVQFjXn2qNZ8sCB8hHpSgNIcyyLGg45OOKAJwQgG0IvXpTiRg/NwPeq4ksTkJPFIy+j5p8k9tEgBAGR6dqAJkkQscMOOQCaUspH3lz6GqgnhuZWj2HK9Djt7077KrbcHJ7GgB012sBBYbm7ccfSrGmt9vZn/ANVCo+fjJ+grFeCWSRyxJCHAGe/rW34fkWLzorgGMPhlZugNAF6K005XIEDPjqWNWFSxi3FbZB+GactoDlhMoPUYPc1FIlrFnzbtV4wduKAJo7yJVZUt9vPI4qQXmBzGB6AVmNqGiwBVkvly/q/JqKXxR4btHAn1K3Riejt0oA3XkJUEY5ODxXNrHLBqU8csgWLedo9SeQBWT4g+KnhTSVBGoxzyEHCxDd+PFcBf/HPS0aRrPTLy5dmOZHIQH8KAPXWhx0fgc5Pf2pgiYkkPHnrjFeLN8c98gI0A+UBjHmck1rWPxm0S4sp5buzurS4X7sQG7d9DQB6bLOUySAQB25qJZWfHlgMucYxg1423xvWOUrHoTvETkb5cH26Viah8bNfkJFppljbJ25ZiD+dAH0GHYfeTZ/vMBioH1bS4hifVrCN+4Mw4r5V1rxrrWuAi+vZF3ZBETFQR6Vy/krIRu5P8RY5oA+1Yb2zugPsl5azD/pnKCTU7LKFy0bZPTvXxHEZLd1e2klibsY2IP6Vt6X418TaVJusNbvFx2kcuD+BoA+udyuSCqnvyOTUE1lBKOAUI6YPSvB/D3xx1WCaOPxFY297bZw00K7JF9/Q17BoXjPw7r8UX9k6vbNcuMi2mOyRfbBoAs3OmyjptlA6djVHVIkvrL7BrtlFqFiRgxzLllHqrdQa6y0gubhWaNFJX7y55/CoZUBPl3CgHuHFAHz34z+Dkgilv/BUzXkKjc2nzH98g/wBk/wAQrx2RJra4ZJEkhnjOGR12sp9MV9sT6btcvau0ci8qQcEH61xvjrwbpXjJCmsJ/Z2tKP3Ooxrw3oJB3HvQB8uOgnVpIRhxy0f9RVb866Dxd4Y1XwhrLWOrQ+XIPmimTmOVf7ynuKySi3HKAJN3Ts30oAqtxUR5NSkYyDx61Cw57UAaGaO9JiloAXFKBQBTsflQA6CNpZVReN3f0FWY4Zb68htbOJ5ZHYRxRoMsx9qn0uxubyWG0sYXmvbxvKhjUckdz/8AXr6I8A+C7PwTahsR3HiWVMzXJGRbg/wJ7+poAwfAvwzsfD8cWo+KES91c/PHYdY7f0L+re1ehb7i7nDSjzs8BccAeg9KuWembj5lwS2eTnrmtCKJUOY8gHgA+lAFO3sBkPcgH0QdB7VdYDpjAz608sFbCjLZ6Z5rmfHnjCx8I2C+ayyapOv7mD0929qANjV9Qs9JtftGo3cNojcBpD1/CvNPF3xWttNu/sugQLeyquWupvuj2AryDXtYv9e1J7zUp5J5HJ2Bm+VR6AVnyn5FkA5HytQB3l98R/E1zxLKkDOMjauABXPal4m1bUbER3N7MypJyVbGfY0aDoE+r6TfX4ExW3AI+U4NYg2vJ+9YrEDyqCgC3bXVzbTJcWVzcL5JDli3Ga6/S/il4kTUll1S5S+s5CEkidACF9VPauNnV1tlYDbbysRGpPOP8ar5R2AfcVAwR0yKAPrzTo3FmlwrgR3MQdGHPGK4X4gfEBvC9mLCwCz6xINwDfdhU9z7+1eT+EvG2reF5ituTdWLgBrSZiQB/snsa3PiLbWfiGNfFeh3Be1aNUuYmHzQOOx9vegDkNR8V+Ib+fzbnVrlWz0jYqB+FQxeItdjYmLWb9eP+exrKPzv655zTRzigDfHjLxOIyo16+C56CQ1Wu/E2uXkSpd6vdyIRyC5/Wso4IA5H49KJcNghSeMHH86AHs80rDM8jOvJYv0p7lpds8jyOrdCTnJqFZAIGBXJboy9hS79yLGxOxeRz0NAD7ePe2FwrHu1ThGZCSEU78cnrVYB+i1Ms5ji+QA47nnHuKAHyqI4cA/MGINSzQs0McyIfLAHy+pq1p+jXWqTTLZSwt5MZmmQtgqB6dqyVkklU79xCk4UdhQAkzGSU/LjPT60y4jaApFPkHYHA9c0jDYw3qXU8kA4/DNJfSeZdlnTy1wAq5zgAUAQMwwoGQBz+NSRp5kbFT+8BAH1NRSFWVdikDuT3qQEJagHqZA2e/FADGJicgNgj5SRTJCVijGMZz+NTXkE4uRD5LGSY5RByTnvV3UtHltZo0uZIIlWMbiHDYPpgd6AMlskAnp0pVVvOUxMyyKMhl4I+lT3Pk7EFoWlReWLDHNMsJl/tKN5WSNAedw4oA9S+H3xo1Xw5JbW2ug6jp6DaZf+Wyr6e+K+ltN1nS/EWkQalp8sV9pso/1i8tGfQjqCPzr4QmIWTaDnJJrf8DeMtY8D6ut/o0uYmI+0WchPlzr6Edj6EdKAPsq8sfIQXFu/nWuOWByVH9RWbdRw3UAztdTyrg/qDTvAPijTvFmjDWvDrHaxAu7GQjfC+OV9vY9D+YF7WLdYFSaAFYZmHyYxsagDi/Feg6dr2jro/iFGltRk292g/eWzdiPb1FfMHjXwtqHhDXZNN1JQSBvgmT7s0fZlNfYjorLsYAo3JGOtcn4z8KWnifRm0W+2q3LafdnrDJ6E+h6UAfJjn7Spz/x8KP++x/jVTj/ACK0NW0+70jU7mxvo2hvLWQxyKRggjv9D1qAzQscyxAyHqRxmgCWlxQPrSjk0AKoz9as20Pmuo2lssFVFGS7Hoo96hVSxAHU17Z8F/CaQ+T4k1GIPtLLp0Dj77d5voDwPoaAOn+Gng9vCFqs95GreJb2MByRkWkR/gHox7mu/tLRLdQXw0rHvyQadZ2xiUySsXnk5Zj1Ge1WTgklhjjmgBkrrHGzO21cjJwTjJwOn1qRV3E8jHaojI3mRJHzI3ocYFec+PvijZaLO2maJtvr+Nwsr/8ALKP1Ge5oA1viT40HhDTYV0+NJdVuWPl7uRGO7GvDYrHVvGXifY04lv7ghmmkbgL3x/hVXxTrt9rGuXF7cOQWIUL1CjHQelV9K1Ce2vEeCcwTqflYdfwoA9E+K3g3Q/CPg/SbeySefUTcHfducFx1PHp6VxHgXw5L4p16PT4ldoUYPPtODszzU/jPxje61Ba2l5+/eA7mlbjJ9AKueCdWudE8N6zqmjSFNXv3TT7YhcshJyxHbtQB7rpM9lZxavFOltZeHbaIwRFlxuwvP17V8rMFa9nkh/492kfZ/u7jj9K+k/HvhrUtT8HR3U+oLDJa6fuuYGjGJHwMkehr5rtW/dIcZ3evagB0hBlIGQAcLk9K9c+DnhTRfFmh6vJq9t5rwkQq8RIdM/xV5ZbQS3c4toIjPMxyqpyT7Vd8P+I9T8P6hLdaPdS2sjHa8f8AC49GFAGp8Q/DkPhPxENMguXuIWiEqyOuCAexqh4T1saHqwluFaTTJwYr6DqJYz149R1zXSeLNdfxzptvdzII9V0wESggYli/vD6Vw0ZaYeWqgq7Daccj60AbfjXw2uhSQXemu134evRvs7sDjH/PNvRhXO4OV4HPGB3ruvh9rMVvcz+F9ZKyaJqJMQDfMsEx6OvpXLa9o91oGt3Wl3ykT2rlckffXs34igCkA2TgY9BipbRxFcxM6mVEYEpnG7HamgM7/L1Pv0qLGMhPvDj6UAdpps3hLUNQuhLDPpLyRl/MPzxxMB0A9DXHyx26yH7NcrPFn7+MFvwq7pEz2z3E8kYaFozFhhwSay4V8uZsqo2gjGO9AFiMKw3MWD4wMdKfp9pdahdwWdjbtcXErhEjXqcmoxtMJGXaYYHH3QvrTra5ubW4S5s5mhnjYMsicEYoA7HxLpFz4OhbSL65t476ZN5jg5KoR0Zu5rjC0eIkjAjXZhsfxH3q/qF1dareveahcGSVwFLv1/GqmxUn/efvF9R0oAhhSGX5LibySOFbbmq8sSFH2yEsp2jjqPWra8SnbEWY56jp9KZDHMz5TGF4+YcAepoApFJAVDjqPyFV5SGLeig/jXa+F/C2l+I1vBP4mtNP1CJS0cEq8SAds5rjtQtms7ya1kKs0ZKllOQT7UAb2p60kXhzRbOwgWPUY4G+0XgGXYE8KDXOK7bTvy27rk8k+tIWKjAJJA6Uo6Bmzn370AIpI6E49uM1Zs7X7S7P5kI8v5mVjgke1WILe0N6RctMLRVG9oly4z0wO9Xj4ZltLhpbrL2qODGCu0zDt16UAVteig06OG3toybthvmkft6KvtWI5JIJOc85q5rN413fSSMAozwB2HpVNgpyF/CgDT8NeINU8MapHqeg3slrdoeQDlJB3V16EGvqvwP8UNP8e6BNCYRa6xEB51vuz/wNPUfyr5AkIDbU+bjHTvV/QdWvNA1m21PTn2XVs2eejDup9qAPs2NjIMkYP161HcxefA0JwGYcY/gIrI8GeI7fxd4bg1ax/dljtniB5icdVrdSQcrja2eQetAHi/x68Mf2jpEfiO3TdqFiBBfhRy8f8Ln1I6fjXz+RzxjH0r7a1ERoxFxEHtLpGguFI6owx+nWvkrxd4S1PQPEmoaZBZTXMFvKRFKi5DIRuX9CKAMfkGpAOTTB16VYtYvOlC5wg5ZvQd6AOj8AeG5PEniWx04fIkreZK5/ghXlj+PA/GvqTTIYsrLFGsdrAnkWyAcKg4H+NebfBXRPs3hmTVGULc6w5jgz/Dbp/iT+lesRKFRFXAVR0HegBx69uO1XNOshd5nmO22DYXHWQ/4VBbwPczpABgv8zN6L3rS17VrTQdGvdSugEs9PiLD0Y4wAPxwKAPKPjr4tXQWOjaM2y/uogJCn/LJPb3NfPCr5Y2lTnJ/E+ta+t61d6z4gutXvWDXM8m/DchV7KPYCqEqb7giGRsFsjI557UANugGjjkDKSRh8dvrUEm1Y1ZNxkVsk/wCFdj4F0qyn8QrY6xEsySxO0kRPKAc5+tVNbtdB1SO9u/CbXaLajfLbT4/1fTch7igC34O0SDWvHOk6fqET/ZrmP7QGJwSmM55r1HxE1r4HhuzYadZrYEiS3WRBlZDxuU+vNef/AAr1sXvjXw7FqnNxbqbO2uF4BQ9Fb3Hat/44yR6vpsN5pzmWPSrtrO9x/wAsmI4yPwoA8213xJr2sSFNV1a4uIsnCByEx9BWKoBJCgYUZ64pyttYqBt561JZQCR2BYKNpY7jjp/WgDZ8E6nP4Z8U6NrTWYkXeVQNwGzwSK0PiVo13pHiy8e+tERdRAuoWiPygNyRWNb6mLnwncaVdxgy28wuLOYn5kJ+8n0PWqdxe3N1Dtu7iWTacpvOdvsPQUAMjMkCC4jZlVW2nB7+h9qesrRszQHy94ySpxjPar3hCyk1HxNp9riJoJJVWYTH5Cmec59q92vvhl4PupNyWNzGyHaRHMQrDtxQB4DpNlNqOpQW9oo81pVO7suD1r6F+JXgxfF2mWzRskGr26hVnI4cY5VvxrQ0Xw3ouisp0/TUiYEAZwSfet65jkdiecA5/wDr0AfMmq+AfFGm3AgudLlbePkkiO5SPXIq34r8LeJLOKyurjSGS2lhX96kfJbvux0NfRFxDcqgigl2hjndn7oNPttO+SNpJJLiQjjc3BoA+VINKv5yFSCU88BQTV9fBfiGSJmXSrpgPmyExmvqy2gEBXZb2kbn/nmg/LNTys21vnJbGfagD49ms7jTIpo7u1mtZGXB3rg1oXKeFW8J2UllLqCayXKXEcgyhHqDX1BrGj6drMLwarZxXEbfxbfnX3zXg/xC+Hx8PyJJYKXspCWjfqf91vf3oA4FXDqFLq0S8EYxk1fbSGOjpqcd3byWpJVlDfMp7Aj1rPljXfhAQw+8PQ+lRg7bWSJ1+XcGI9TQBLb3Uos2iZ3VVJKAAEn8arOp8sqcANyT3+lTRhoWDPFI3GfTNRXJd5Hc/KT6fyoAooqxzFyoIHtmq54kZsk5OcelaKpgOWGRjqaoSr5b/eB75oAIbd7q5jhhBaSRsD2+tLND5crq86FoyV4OTx6UxhLEwLB1PZgPX0p6tELd0MSySnBWRc7l9QRQA+CVonN1HLJG6Y2Mp5Zveuo8XeK9U8cvYK0cUYtYdn2dWxuYD73uTXHEMRjt3PpS8IpOT7Y60APvLOe2VTcQvEW6bh1qCIFicAAep6U/e7P952BGADzipb/Tb3Tobc39rJbi4HmRiQbSV9aAKolKElMFv73pQrlpHY8k8k0xuDxTy5dcqoCqOQKAPRvgb4uTw14r+w6g+NJ1MiKX0STor/nivpOeMwSlSQGTv6j2r4kVSyFuijgH3r6n+EHir/hK/BkRu33atphFvcerrj5XoA6y/X7VYynPJHABzWZbapbxwIk9pHJIowWYDJrUlDmN2X6DHeuSuU/0iTa2BnpQB8vDI+laEFrJO9vYQZ+0Xbohx2LEAD9arWqDDTPykfQH+Juwru/grpn9q/EC3ubgbobFGvJcjIJAwo/76IoA+itGs4tOtbWxgUCGwgS2Qj1xlj+daY7HcB/hVTTz5lqZG6ysXP51owQi4miiBOHIBGOg6n+lAF6CKS3sGlg4u7rCx5/gHb/GvF/2jNckjn0vw1bSMtnGnn3B/wCejdFU/wA6901G8isLeW8mICIu1F6V8++GrKb4heKNZuNQCy6XK5KTMPuEcfL9aAPKpo7ZLd4mL/a0bcGXlGX0+taupXmnzzxG3gEKGNFdI179/wAa6Xxt8Om0GMXNheeagzvtypLovqMda4lomsVa6jfBAwgdeWB4LCgCXTdUOj+IEvbRd7Qlly33sMMH9Kt+B9Ma08YaZ5242F+z2kUq4YSbx0OP1rnXdUUso+ZupzkmtbQtevtL0u9GmXawSyDDApkgeqE/dPvQBRv4zpmsOtmzeZbXG2NkPO5TwRWnDNP/AGnqkN5dTyx6tbmVgT/rJByNw9RisAtxv3Hg5yT39a7X4eaRc+J/OsLVAby3QkXL9Iw3HP1oA46aAxQW8qMHV1GeeVYdQRUO4qu8khehH9K0fEGkz+HNUvtL1ARNcw43vG2VB7c11I8CXg8Jw6gAPMdDPg8gr6k9qAOFcAzM8aEKegJ5qe2G4kNEG43DzOF+tT6vaWUC2J0+/W8aWEPOEUjyn7rz1qvNPI1hEjMSgbaOP0NAG14VhafXrJnaFIllXILhR1+tfU2wzjcEjUKB0PUYr45cKY8ZwT1wa+n/AIQX9xqHgmyuL5y00H7nc38YHSgDqRbKrE7Rv69am7EdQe1RySKh389eBmmSTrkAA5z/AA+tADJWLXCw/wABPStJMINq5GOlZcLN9p37PxPatVTwAOSQTz3oAUg4GQcnqRTTx8vbPJHelJKptzjpk9vrQQQ7H5lOBgdQPcUAJ0bAxk859qrajY299p81peR+ZBKNrKex9R71YwCcHknj6fjTlJ2ndknOQMdKAPmT4g+HJvDessgDHPKOBw6eo965BEE83ClUY/MRzX1b408OW3iTRzaXBAuEGYJR1U188axozaHqZtfLmQoMsWHJPqB6UAYF1v2+XmR1X7qEZwPXAqO6UrFD5iOkhG47kKnH41YmM9pLHcRz+VOPnXHLjnv2pNTu7m+uJJrqR5XbBZmAoArr9piiLqoVHOQWX09BWdqtzLcRRmTyyYyQdqbT9TVubzCyhmJx90A8AVCwRHVbuNpYWYB1Q4OPY+tAFeKNrhLeGS7jGf8AVhicKfQ1JDeyaXLdW6NHIjDy2ZRyD6qah1WG3XVJYtN3m2Ujy/M+9j3qvOCkh8wqSepBzQBLqLoZg0XAZQSD2/8Ar1UIIwMZY+tTwwzX11Hb2dvNdTsPuRIXY/gKjuI5bSSSO6imimTrG6bW/I0ANLOgIjYqTySKm1DUNR1h7UXtzJcSQR+VGZD0UdqryAHADcYzTBy2WzgcUANbIzkEMB0Nb3hqPSLi+sLTX5jb2TuTLLH19hntWG7b3Ytlj0B9qQ/LgkA49aAOw8Yr4ft4NP0rw1asbuNnku5xJvVz/CvPcCl+FniaTwp40tp5pAtnckW90vbaTwfwOK4wMdxIyOeoNDgsrLk8jHvQB9sSqfNZVKlOGDD06/yrLlsg8jMqnBOe1Ynwy8RL4h8A2FyxzdWafZZl916H8q6ASkjPrQB8izEZSFCCidx3Pc17h8BdNa38LavqZGJb+dbWI/7Cct+GcV4UvCnauW7Ad6+q/DemDQ/DOiaWvL21sC56EyNyT+lAHUWIC2qJyVBxWtozxx3jSSsFVEIDH9ay7eMRRKoI3ZySahul81VwWxkHg0Ac78XvFKWmiXUyAneptbRQeSzDl/yql4T1Ut8NkXwVbx3OsW8Kxm34Uq3QsfWvNfinri6t4vW0WRVs7D5CfVzyx/DOKPhZeGy8TYhvyolwpES/6znjigD3W1ivZNGgGoLFFqzQ5lDKCM45H41574wi0TU9ObSL+Iafq9tG0wCx5Cgfw59+teoyndICwyf71ea/GLSJ7mxS9swqSL/rWUYZx7mgDwfaQCVB5PPHSrGk6VqWsXqWGk2cl1dOCRGhGSB9ajDsFManCnt70sUkvnxizeeK4XkNG5Vs+oIoAr3dlPY3EltqEDwXCZ3xN1B9DXeeAviJD4R8O31tb6NFLqc0uVnLkblwfvfT2rjIv9IujLcGWZQ26Qhsu/qcnvVNpYw7mNG2g4Bfkge9AHr3hrw9pXizRrG61lyl9q7TTgoCWZo8Er9CKdceIxZeE9Qt9Ul/eatA4t0jICQKnyKgx3+Uk/WuR8Ma/rhsbDS4bZ5oEkZtPeFNsyOfvBP7wI4Iqn4tvFn+y2P9kz6XPZF/NikYnezHJbnoaAOYhUxsikZAxkDvU0hLWzqiFY/M3AE81q6Lp8OoS+femaOzjOJpIlyUHrVO6jtUu547Cd7i2yQJWXbkfSgCHTrSS9v7a2iG6SR1GOvevqTw7px03SYNMiIAjG+QKMYbvXkvwR8PefqN3q13G6x2qgQZHDOT1r3SyhEMeOkrfMx7k0ASRW0agD75Pdv5VYwN6bY1CnIJpFHbHOeacBtXgEnrjHagBpiXgrkYOPY1KuQpDc/UUAZY45B6H+ppQDjAA5HHNADW4BDEkjrgdaUAZAGeOTSnp/P2+lJ1GFGB6CgBdoxyePX+tAOFxzjr1o7gj6H6ULxnrjP+fxoAR+hXt6ivHfjzA4tLS7iTa4YLIR1I9M17Ec49s5Oe9cB8Z7JpvBdzJGMNEwbp2z3oA8EIsThvOlM7EbYgm78zUUnlNdJDczPawO+3zWj3Y+oqGOaNSJI5HQ8fcFFzdi4CI5YhSct3oAu6pa6fpzSwWl7/AGldMQWKptjiX69zWNOwTO0LvJ656VMF86dY9wG4du9MIOT8okcgjHpQAzR7Q3t7PGc7kjLZFZEgCjkHryMV7N8EfC8Ouwa9dygboFVV9+Dml8C/CxtUtNW1HU8JAJJBboPvNg9R6UAc74R8bz+B0a28N2dnc3dzGrPeSx5ZM87R9M1p+NfDmua9HF4h8SGySeWEusaOFmcY4wvp71yGg2C33ipbKAkKkhzz2BruPHXh2HSIj4q1DU5bi/kT7NZ2sn8A243Z7gelAHj7MpYgR7ccGlgNmqlr1pUQngRjJPvTQGXCk571XnYM59elAHQ+LdM0LTDYf2Bq0mopPEJJA6bfLJ/hrFkZVhKLGHeTGGP8NMbaygt/CMfUUilmQKB8qnPSgCN1Mbsr5BHWnsu2NXJ5foO/1rS0+wtbmSR7y5lS3jiMo2LuZ8dhUGpkrcKvy4CAr8uCB2z70Aemfs+XbprGpaO0mPt0SyQgH+JTg/oa+jJfC14HxDcR+WAMbhz05/WvjnwBrH/CP+OdE1E/LHFcosn+6xwf519u3i3j3Ltb3OImwVx6YoA+Lvh3pQ1nxro9kR+7acSScfwL8x/QV9S24S4ut7L85YsTnjHYV4h+z3p/maxrOqMvFra+TGe29+P5GvdLC3MEshkZcqMDBoAtycoRxnNYni7V08P+GtT1OT70URWIHu54AFbMgDDB9M5ryX9oHU2W30nQ4SzPO32iRFGSQOFH86APHCzyEzTyB5JSZHbPO4nJr1f4J+FZZrp9Yu49sYAERPYepqDwL8LnvJor7xBKkNmRvSDI3P8AWvbrKG3tLSO1s0WOFBgInYUAOKnBHTJ5rE8SWEl/pc0MRJYDIFbj5HQjkYxikDc9zx0x0oA+Vte024tbyYFPLIJJqra2U80aywqRngkdRX1Bq3hnTtSk86WFNxHzYHWse08C6VZ3O6JHWEnO0c4NAHz1bxC1lZXUjJxjpk1mTATPKISsRkJwCOAa+l/EPhPQ30i4DWcYUAv5hPKntXz3Pd6aLi8g/s/zYtpSKTzNro/973HtQB6p4L1zwrNrfhLR7eEpLawlft8w2mC49EPcNyKy73wvpfjTxBqNn4ahu9K8TW14fttrfzZWWIt80iZ6Hvj3FeVxh9ow7KykFXXghh0I/GvatK8M3vxFTwx4rXV4rLUYMWl+65V5jGxwwIH3ipAOfSgCnDpun61pPiaz8IyXVmulOsSiVCftZHDkgc9Qa8y13SJNH1J7Nru0v5eAJLR96sx7fWvRPjf4i1UeMZrS3kn06zgH7gQJ5aykj5ix/iPWuI8HWMd7430a0llXyZbtGZoxjGDmgD6F8F6Pc6N4R0bT7wZuFjDSE9QTyAfpXUAfNjIB9TUsqbZ2GBwcADoAKZIVSUfNjzDtX6/5FADvXHpyp4/GnnvztY8A4+774pBnOeo6Y9KFGFwo+Y46/wAzQA4AFlJBLdwB29aCcKM9++OlGCcA4J6Y9acgwQvAGPyoAHzuOc898U0g7ec4HJ+tHrjofT+tIOf4ce39aAF6HLdT3J/Wg7cMWzzxyaAOg9ue9ICep5J96ACQcZJ4x371i+NLRdR8KapavjDQlh+Hetk8Dt+NRXKrJbvGwysilTx7d6APkXTbZJ3SKVXKqxG6PAwR0zUNuJElZ1MJVSeW5ANW9UiFlrOoW6qS8Nw3txntVF3LS5VSo7rj9aALMFvcS3DGG33nacgjGPcVH9lu7KbFzbSQu4+UnuDUotpntPNdJhbg7Vl6r9OKMRRwO5uGLJgANklvpQB7V+zrGbNdQjIbdN8+COgHf9a9C13XbDwtod1qV2QsMGSFUfeJPSvHv2e7m9Gq6mrrLJaiIhMnge1dB8Rrddfv9L0O1luGurqYM0Dj5MA8mgDntVttHtYItX0fTFs9V1WUBMOcAtzwO2c1P8XfA2vX8uk3Vg9tIgtwrwvKEKPjk4JpfHNtPefErwx4P0XMckLCWSdRzGB1P4DmuZ+JXjWzTXLm18Oma+kgPlyalduW3OODsX096AMmPwjo+gwx33jS+lZi2DYWOC34tWX4o1Lwm0cI8LeHriGE8ebdy7mJHXNYGo6jcalcNNeStJIeDVSJzHG8ZUFWP5GgCYCG6MrKqW0iLvCk5D+w96pF2UFedp5KmnAEDJxk8UjgAbcYx60AS6TcLZ6jFO0YkVMnYTgN7U2ZvPuZpSNoYliM5x7VCCc/SnhsHAGcnpQBFMxMLlDh1G5cdiORX3p8ONUj1/wJoepBTma1TdnqWUbT+qmvhCdWR2SThx2rtPDHxI1jQdCtdMtLqRILcMEUHplif60Aep/Aex8nwJc3ByjX1+VDH+6gx/MV6nZxGOAqCxOTye/vXHfD+yNp4A8NWuSrNAZ2HoXOf5Gu7t4TcTwwL/GcE+ijk0AV48MQqnJ6YB6mvDvix4xij8SG102KKS8sx5bXLjO09SBX0L4jW3srR9TUBYbKOTzMcdFOD+f86+JZ7hru6nuXJLTyNISevJJoAv3HiDV55/Ml1Ccup3Ab+hq9a+MtftZjLFqM28nncc1zmcH/ABpeeMjGBmgD1/wX8YLiKeO18SIslsxA89Bgx+59a9ut7i3urWK7tJRNayruSROQwr40x13EYPtXffC7x9J4Vn+xX5km0eVhld3MJ9R7e1AH0lE24ZKlR0Ge9KSVBYH+tQWV3b31sl1ZTpNbOAQ6nPXpn0qcsQxJYZIwB60AZuqxi4tZI1XeG+XGK841f4TwfY7q4gbNywLqoPAr1NI8XMYJXeRuRC+GPHOB3p1wXkhaOJdzsOnT8KAPkOayube4nV0bEDbJHAwAe2a9A8Cxwa54dk0SfXxoc1hdi+hnJwkowMgnI54rkvGU0y+IdVR2aMebiSIdDj19agfQdXmsROmnXL2pAdWVMg0Aei/EjxhbeNLjS/DmkQG6min/AOP3bzI/T5R6V59qNrceGPEy20zhbiwnRpWTsQQTXefCbT7PQvE1j4i125hgtBG0UMbg7jKR6VwXia4l1rxXqssaNJc3t2wWNRljk4FAH1wzpL5c0TZSWNWBHTkUmRuG7AYcc1leGUnt/D+nWV4Va9t4VjcitTPPXnuaAHqp3cKc4zjFKcHjOMeh6/Sq75bzA5BUHgAkZ4FSQbgAHTAXIGT0oAlByRknnv0pc/KMYUkcjOc0bhgMSfT8e1HPXOcdKAG5HuPUig8jrjHoaCDnGVOD36CgnDBiQD6kdaADJAyozt9aQ4I7Dvnv9PpRg84JzngnoKOC3A4Pr7UAI2SxBGTUF42Ig3OCeT6/WrGOMk8UhB2MAAS3Xjt7UAfMfxE0p7PxveKCEFxiVCx6ZrBurSV7hRLIu4JyF9BXuXxg8MnUNGh1exjV7q14kGOSgrxCytrjU7+KDTxm6mO1FzgD8aAKdrJLzFEWER+cx54z64qa3uDZ20wa2il8wYMkgJKY9K0j4c1yzMi/2cZ5t+zMUgcADrVF7bVHSa1m0+4RlyW3RH5QPU0Ae1/BfSnsvBUd3IxEt25lORyE7Vu22iXE3xOs9Vilj/s+HT5CkwOSspPQj29Kw/hjrHn+DICRmRF8sL06cV1UsM2n6VHtwtxNudgeOKAPNZk1Dwtouv8AjPxRcxXWvX4fT9OEfG3eSC4/CvCTtXCbSGGd2TXYfEvX5ta1r7PlxaWJ8tAOit3OK5mW5tZbFozast4zDfcFvvAdsdqAGX99LehJGihj2IFIjXHTuaok5bLcA8mldVydpYY7GpJXh+zWqqn71N3mSA/ez0GPagCAEHkAYznrTpHaQhj6dDTp3WTayosZK4YL/OojkEAcMOnvQAoc4fAX5uuBWno+l3l9BcTWsKtHa43M7heT0Az1PtUtybCGysvNtNuo5DyFSfmX37CrH9r28aRxQqBDBKJwhGd7jpQBz8qGN38wEPnDA9aqyD5z1FWpWaaWWViS0jlj9SagYcmgD7XtoRHerbxgCOBVhU5x90Y/pXSaEn765mAO6OMIpznk8/0rntHBZ5JDgsRlsj866jQgPsV1IBjMhGPpQBzfxQuPK+F3iaZByISDz1OVB/nXx2oARVzj5Rj8q+rvjhJJa/CXWtxU+fMqjZ0wWH+FfKgC7huGQFOAKAIwCED5BIPCn0pASQzdOx96GHQ5ySMnHY0gPykbjg9aAHblXaVbnvkU4EHOOh5qPPzYA4PanHkcjHvQB2fw98b3ngzUAGDT6VMR58HXA/vL719NaNfxalHaX1rJHPp1wA8LKeT7H0Ir41RhleCV6Yzmuu8D+O9V8HyPDbhbjTpG3Nay9Af7y+hoAr+Mtf11fH2oahe3U8Gp2lywjAYgQgHhVHp/Ovo7wbd+Irzw9De+Kra2tbydlkjEZAyhHBYdj7VyujaV4Q+JN/F4oMVxHqdoV+026sNkjL90sO/Ssj476f4t1/WLKHSbO7udI8obI7VTxN3L46e2aAOz8Q/DnQ9avhdXKPHMXEkoQ8SY9a6u1SOCFIbeONYUGxYwOMemKz/DMOo2fhvS7fWH8zUIbZUuGByd3YE9yBWgpBYFgB/tZxmgDM1LwxpWoypLd2ys8J3RqvCqfWlsNA0ay1B7+10y0TUCMGdVGfw9PrWsD8wAxn0amyq7EYbYg6ju9ADZI1ALFRuXrgYJP9aRpVVQZ/3a8YY9z6VNgKCVyT1y3JFNYMQTnOeQfWgBV3bSWBXJztPUe1PUncuDk9ee9MXGeQfUAc80qnDAscgfNzQA4KWdXkOHGdi54Hv7mnY28cEn04zRjDAZ5zycdaTJAXaDjuQaAEJwu0nOecGkbHHI/wAKC3cnrzwKZLIofC7VI5POaAHgngt05zThgtgZz61VSXEoG3gnBJ9askYbnJIGOlACDOCf1xn8Kcdyr0KgDg0nGPnxzwPelLcHjgfjQBC8azxvDKoeOQFXB6c189eIvAeuWni+ex0PTZpUnyY5Qdqop65PavonHJyMr1KjvTJpGZh8wMajaCD0/wDr0AeK2Hwh1mwspXOr2y3bDd5UG4EH655Nefza74k0qXVtMfVJfKz5M6O25vwJ5r6nQYkAJwFI696+f/jF4Ok0fWtQ1sNJJa3kodCOzH+GgDQ+Bhm1K8g0k4ZYXMr45wvYmum0zxJN4l+P9xoyyB9EsrWWHYAMAoBls9/mbH4Vh+DLSf4d/DDXPEuqL9m1bUo/KtYm4aND0P15z+FYHgASeAfA2o+NtTDnU9WQ2WmxPwW3ctK3tn+VAHmusyF9Z1Ly2wn2iUgZxkbjWzN4YurfwbBrccUtzFesEQbcOpzyQOuPesGxSK4uIY72UQ27ygS3OeVyeSfavTvHetWF/wCILK30KFdVube3EU1/HctFAQo4CKDhQAOTQB5aYBEJRdpNFKF/dqVwS3vUCoH8tISzNgtJkcLXSeI/EI1u20y0e2WzisVZd6uZWkJ6lmPJ6VU8Oaf9qvllRVkhiR5JVJwCoB/rigDEjkjXY7whyrBhz19jTp38y4knWMqZGJ2Doue1SQRGfACKis27A/hGela+taHJpaRS/abW8gnX5JbZw2MdQR2IoAwp1dZ3WR9z9yDkH8aJ/L3YjzwOvYmpFVNzEgEdOeMmtnT9K1W6toha2q3Vo0hWJwm5A/cE/wCNAHPlMcmqzkbjwK3tT017O4mivJYxcKdpWPDKPxFZsllhyPtFsPYsM0AfamlRPFC6uBv3betdFo4P9nyr0PntWDAoYNk/xE8mtzQiGhu4C2GD78jng0AcH8doz/wqLUxgnZOhPt81fLDfdYgE54FfZHxUkSLwZfQCJJWMDybHGQcDHP5/pXx/JK81lCs4DpGMKQMFaAKsEixSCRkEjf3T0qNupyOSc08R/MAuSSeO1R3cMqiSMHY4ON3XBoAkjl2k5QFs8GpIIXu5Y4bZN07HGP7xqNLd9sVvBIbnK7gVX5icc5FOtzIJBJA5jdOQwOCMUAOlRkuxF8okQ7Tz3pSWSRlfa7A4z1qxd6bdW1jY6hcGLyr4M8W2QM5wcEsO3PrVeBFeYb22L1ye1AHY/DrxinhHWEkkt/MtbgbLnBwVz/EK+k9JvoNUsFu9IvI7m3cfK8TenUEdc18fOEeUmIsQTgAjtWn4Z1CbRdfsbu3nmWK3mDSJHIVDKfvDHTkZoA+tkYkhsBWYcccVJgZYjv1JHavAfCHxPutJ1cQ30Zk0CS4YFWO+SNWPBB/EV9AblKo0bkq6B1OOqkZFADY33E8ABehPr6048DDHgdSO5ox8/PJz+dO25ye3tQAcliSAcDrnrTH4G0fn2p4P3TnOaivJIrazmuby5S1s4hvmmkOFA/rQA5TjHUAnjNPXdt3HlRycd/avIdV+Nun21y0eiaRJeQKcefcSbN/0UA8V1XgX4h6J4xuPsIjk0zV2GVgkfKTf7revtQB3GWOfmBIHGaaemAB7GnbApwOOeuev1pjHYAWICjk0ARGGaadlBIjUbiTgAfj6VyOs+PvCWio/2jVxdXanHk2wL/8Aj2MfrVL456/NongRbSykeO51aQxl84ZYhy2PTPH618z4CYCqAAMUAfW/hzxZ4Z8TKn9majEt0ekExCPn2zXSukild6lWPYjAP+NfECsVkDoSjqchlOCPoa9q+Cfj3VrzxBbeHtYu2u7WZSIHl5ZGA4GaAPcUBA3KW9h6UYJBGA2OQRQ2EZlJ27T+dIfu5P4c0AH8IBOB/P8AGmYyRsHXsewp4P8AF29OuTTSOoJwx6Z9PWgBo5GVIYA8+9JdQR3FoFuLaKZciRY5ME8HqAacp2srKBj+L2rznUvB3iiX40w+IYr1Bo2V5aYgCMA5TZQBreKfAzeMNZsbnXbtv7Ds1L/Y1481vf0FZni8eCNbM1/dXsN4vhu1b/iUF9sJIHyg+vpxmuz8X3+kWmmyNrt39i01pF/eAkEkHIHHrXhnxB8CeHJbTUPEngvUn1O1imV77T4XJdVbklTjP6GgDl7P4lTLC8d74U8M3UDjKxG18vyx6AjOa0k8QfDfV5o473w3e6HmPzJJ7O53KZMcoE/unnmu2tPhX4BudCj1y5l1qxstgkeGSUE4xkgcVi6rrPwo0rRrefRvCn9qTTsylblyjR49Tz1oAteGPBfw78S6asmlXOqRlmIKSMDID6deK6n/AIVZ4Ys7GSKKOcSTBVYvLywB6e3/ANauMf4paBoui7PCXhldOv3H3n5C+/vXBaX411qDWW1S7vXn82TdLuJ59Ao7UAdz4/0vwV4WhmsYxP8A206hwkZyFHoT2rzbUdcku7e3SC0gtooFKs0a5LZPeqms6tNq+oXd7dcz3L7vXA9M1XkkbDARiMEKCB3xQBt+HbjQmu3bX47lo0BMa24A3nHRvbNbGifEC80S3+xafbRx6NK7NPa5+aQkYyG7HmuReEQGAytzIu51xgoKjuvJW7lS3ctbg/I7DBP1oAlvGguJ5pNLR4IslvImfcyj/e71kMoZiduferRglIDmNtrKWDYOCPrVFmwxwaAPue1A8hCGJDc1atbs2VzHMMlXyjL7darDy40/3V4z1psql40IxuU8c0AUPFkraho2uSMP3jWrrGrdAuOlfJ9qI3gYzzNGFj4A53N6V9dXkTS296g6PbOvHTO018gMApZeQVdl/ImgB8cMc9rI6ybbmM52txuT296hFvcbVcwTKCflYocE1LHOY+NqMQwI3CvSpfElpPqp1e51ia0aeNAmmGAPFEQMZGeMUAWPhLb6T4aW617xYYLJLhRBaC5+8c/eIX096wvivoVhomq2qaPCBYTx+etyrbkl3c8H2/rU+p2NnqelajqmuXNxqV/AyparFINroeuPTHpV/TPHPhk2mm6bqukzS6LHbmA27NnyW7MD1zQB5aEwWIHXqacADnOB/WvY9A8B+C/F+km60G5vbC4ExVopn8wqo9hz0xg1RvvhJbm9uoNK8W6ezW5HmRXibHUH1PSgDy6MSKiPgiNiQD2JqzHC32a4cPFkMo2fxMT3FdTrHw38UaXDGwt4b61Z8RtaSBwc/wAX0rH0YNo/jHTotRtRG0F2jPFMDhiDwD7E8UAVU8mSwdfnWePIdfUfT64r6U+G2qtqfg3RxcyobtYdmN3JVTgfpivAdX1NNQ8Sz6m1nFaLPdSRTQRfdRSMcfzrrdEv5bDw7KdMuXGo6XMnlw7BgICSZM9TkHGD/doA97Vsgkcj16D604lVOTkd8E1iaP4p0bW2h+yX9v58yBzDnAJPVfrW2wZPvDB9OtAB8pU/3ug968a/aK/tyaSyKxzN4biiGWiB2CXv5n6YzXsiP85XgngkEUrjzbeWKZUlgkBWSKQBlcHsR0oA+LhyMip7O5msruC7tJGjuYHEkci9VI717xrHwc8P6hcPLpWp3OmEks0LR+ZGvsO4qC1+BmlNgyeJbqVf4lit1BP0yKAPTfDWqnX/AAro+qyL5VxdwAyDHBbHJFXZGVVO8Z+YZx2qhoWlx6Jo1vplo7vbWq7YzKRkj3xVx1BkOVCgjtQB5n+0Bp76j4Y06a0ilmubOc7lRSx2MO2PpXzw5A4bgg9DwRX2lADC4aBiOeATwKydT8LeHtUYtf6HZTNnLMq7CT9VxQB8g4znpzXb/BjTrjUPiLpjWyMyWredIw6KB6mvbJvhV4JuJdx0ueElcYjuGx9evWug0bQ9J8K6VLa+HrEW8b8ySMS0jH3JoA1LyaH7QzO5Hp3z7UkTiVAV27cHHGM1HbRAAF+S2MEDOKmYNtJ64oAaeSCQR6HuKUcNk9e/ekU88E/TrTgOAQo4GVxzQA0AF8c4PoOhpCP3mWy4HQ+hprtKWASNdjDIbdwpHqOp/ChVljjIln83nKllCn3HHGPTv60AZPjbSF8QeDdX011UO8JkiZhkBl5zXybousX+hXb3Gl3DW0rDy3IAIcD1B4NfZ1vGLkPBgkvGylR7qa+KdTjkstWuoJU2PBcyLsdegDHHFAHTaj461vWdPWG8uFkeL5Yo1G1ee+O9Yl3NJp9qmn3MUar5nnSOVzIWPp7CiyjW61CN7ZRETIq7mPyq55/KrtpqJtvFZumjh1cRSENkfuyB1YH0oAyptG1eXZKNNvDbspZZzGdpXrnNZMhyPvZx2r0nWfjL4n1LR59NEWn29jIpj2Rx/dXsBXmacDnt+NAErSJJERtxIp6jpj0pyuvyMM78dx37VEGDZ3ryw4IPAqVIw5dUDShecjjigC3PJE6AM8rT4BeRjx9BTrP+z3bfeO3kqSJFX7zcHBH44qhnCxyFwd+RjutJIiqQc7gwyOOfxoAklu5nhFuZpBbIxKJnpWbI2HIwK0JLaRYkl4ZJMn5ecfX0rPZNzEjNAH3YD2yTg8UmCCDxzz70oAPPHTNK6koRyTjHzdKACFcy7Wxtf5CfZuK+RPEFl/Z2vatZg8Q3UifhuyP519dRsVfIU8YJOcDIr5t+M2niw+IuohVIS6CXI/EYP6igDhgNuMYP1qz5F9qEU9zBBLNHZRhp2UZEaZwCfaqrYGSDz+lSxT3dvbTtbzSRQTjyZgjYEi9dp9RQBDay+TIzYLh1IwDjHvToIZRbm68tzAp2eZj5S3pn1qEAhS6/dBwTjoKmWacWptGlkFvu85Y/4d3rQBJYXtzZTebaXElvODxJE2CK1r671W3Xzb8zM14u7dID+896wdxwOcHIx6Zro/F2q6pqEttBq00cj2cYRAmCowOoI68UATaV4g1bRYxAt7dWsYibyUjfgsw4J9hmtvSviRJNFbWni/R7TW7VJQTdldlwvPY98V5+mS43HnnknNA+bGQQT6npQB6Rqfh3R/EspufAWpNPO0jStpN4fLmz325+907V0/w31PS5rTU7a50C4n8Uwr5U9qr7JJoRwdgJ5I5rxqzuJLaZZodyTIwZJIzhlI7g19FeBVPjXRbDW/EejLHrNtLtttQjzG86j+Ijr7e+KAPK9f8ABWrWuqTLoenXt3YuoliJjIZQf4T6MOn4V6xomtP4M8F6ZH48vhBe5PlxZ8yXZ2BA54FO8dfEuw8Ks9nZ/wDEw1cqSEjYeXCfVz6+1fPmsaje61qt1qupsbi5mf8AeP0UfQdhQB9T+H9d0jxBbmbR72K52KGZAcMgP95TyKsazqtroek3up6h/qLVd5A4MjdhXkv7PGnFf7Z1ZlxHIVtUP45P8qZ4/wDiJrOgfEy900x2l9ocTxxNp8sQZXUjnn+9zmgCHTPi5qMN5NLrlpFcabcSZRLfCtCvt/exXtWn3Vrdadb3enyLJazLujlB5I9PrXkPxI+H9hFoQ1fwvC8cZf7TcRSOAsETgHAyexzXIeBPHF94PuHSI/btJkP7y1dunqyHsaAPpRcnOe/BxTSQFYksMjrWZ4d1vT/EWkx6lpUrNbOdrIfvRMP4WHrWooztGSAR0FACBRk7iT35NP2bkAP3evWm7tuC2RztK+op+MHng54oAacKhCADIwADyaiuYTcQsFfY3v0P4VM5HYc54NNGeBkEHt0oAbagraorkkjg5p5baQNpDD+L1qjqeqWGj25udVuktbdz5as/XPoPWvO9Q+M2jWkzxWWmXd1GCQJCwXdjvyaAPURyR0+ueKVdpJBwDyd2a8df47WCg48P3TN/dEoxj86st8bNPurrS7PR9EnmuLx1jmWV8eUScYX1NAHq4AZ/mbYCckt/P2ryLxX8aILPWJbPw5pS6hFbMVkuJ3xvx12AdvevRfGk407wZ4guJvlEFo4U5wdxGAB+NfOHgvS4b23nt3mFtKsBubi92Fhbp7kdPegC94h+L/i3WEMUNzFpVsSRtsxhsf73WuDuLuSWGV70vcXUjAh5PvAepNaXizTptE1XyLi6guGmiWaG4i4DxnowB5GaxGdtjA87se4P1oA3YZLe/wBKtbTTnh066j3faPPkws2f4tx6emPasm8tp9PbaCkkWNhlt23RtntkVV2bgm7AR26ntVvTL2fTLiSS2YhzGyJjoCeM49aAI/tUdtJbq1tE3krj5lxk+p9aosdzElgdzZYgVfivp0ufMvFW7YggrcLnmqxuGOTHHEnrtXpQAkNtLPL5cUDyFjhMA1rXnhnWtOtY7qe0fy5PlIjO4r/vAdKy3urhkAM7jjgA0sF1dW6yNDdzR+Z9/Dn5qAIiGjdkkQqw4wwwVpFk2EOh+cjDZGasm4Z8m4AkJ7nrTGaLJBj445BoArhsIQin6k9a77wh8P7rXPDlnqMboEnDEZHPDEf0rhZkh8tihZc8DPbPFfcnwz8PW2g+AdD07EUxitlYyFB8xb5z+rUARKSemMGnd+OPcmoiSDlRweoPapQeCFGR1xQAwxs0oEaPIx/gHU14/wDtCaZvtNH1mNWOxmtpTjp3XP5mvadLfy9VtiWIDBl6dz0/lWT8VvDya74P1S3gXDuN2B/DKvIP4j+lAHyNG0RdVuNyx9coOR71Oo0uPTb2M3d5Jc7lNuBEAh9S3PpVXcVQFgPMBwysMYNPjtlV4ZL0tHbSZCsgyaAEWOCK6RZ7ndavtErxrkqp6kA9SKm8RWkdlqTwW06XNpEoWK4UY81eoJHY+1Uwu9SDj72Oe4qa1ZIbuKSSPfGjhzE3RiPWgCFVGN3HTgN3pWAUAHcpHQGr5mtri7llkhaOGRyfLiGSvoAK3tT8EapYaTZarqU1rbW92MxQvJ+92+47UAckA2SQMgdSO1XtH02fV9Sg0+0eJbmdwkfmHAJPvWlpnhXV9T09r6xti9ozFNyt1Ir0r4Y/Da5sdctdZ1sxeTbLviRTyZOx/DNAHReFPhJo2g3sN7qVxLqmow4IUjbAr/T+LH4V0nj2XXo/DF1/wjNsPtbLsaTgeVH3KjtWvdTzmCc2e1rtkbYzcBXPQmvMdJ0rVfh5o/iHxD4w1k3ct7A1vFaxyl/MkboeeAfoKAPH72G3j8gwSSTyyAmZzyd2eageVoxMsbl1kGGUjHIrsvAXw+fxT4av9Vg1uOza1LBopIyT0ySTnpXJ6FYXGp6vDb2sa3OJQpY52EZ7+1AHssF4nwv+FOk3UjG8utQnEvlrwBkbiB9ADXW2fhrwxrmpWvjIWrT3N9AkgDtlM+uP73asjxjouiXOhaX4Q1rWoLDUJmWW035YoemB6A5wM103h7SYPDejW3h+0uDLJp0fzBz8xDH72OwJoAxviffw2Hh1be5s3nt75jC7KQFQDpnnkV8531ukUrK1xbAgnHlZIr1j49W95qF/pUNoZJbeJD+7BAjRurMxz16V43MiLKUUqSDjK9D9KAPX/gBd2nmarp0V639oTYmjgYYVgvXHqa9higm8wvIUIbjYpIA+lfK/gfUho3jTRdQc7ViuFWQ+iscH9DX1nI8UZdnbbHncGB6e/wCtAFGchPKdQykN82Tk4q8GVlVoyNp79sVTwZUdzGwVjkOBuf8AAe9Qkz6a2HTMJOWRzhlB7/40AaLc/LggDoPb1p8IaQ7UAxk59MepNV5pNm5ZUZQQCGJ4rzL42eLpNK0WDQtNkMd3qS5mdT8yw/X36fjQBx3xv8UWuveJLSw066WfT9PUgyJnYZT1x64rzdzAVcSmQEDKben406MxpEkYUqFBB46moWjJcRxqWd8Ls6liegHvQAxLh0ilRXEaSDDZGSR6ZqBZ5IHgliYpNCwZGHBBz1FW9Q0+90q5ls9QtZLefaCY5R8y55zV3wbaf2t4y0KymdNjXKL8w4IB6Y70Ae0fGzSvFOoeG9Ll0xJLjREtEub5EPziTGSW9R3rH+C/h4xaXPrMF0rz3ERjbTvMXdMnuD2OK7T4kN40j8ZafdeHru3/ALAlkjtnsiyqXBwH3KRyp56V4t8VNI0vQvHd9Z+H7pvs5UM3kSH9y56oGB7GgBfFHxD1SfxFdfadF0232HyZbW4t9zbRwATkY49KjtbTw94r0HUI9C0qbTfE1sPtCWy3G+K5QfeCggYI9K0NO1C28UWkUPjLQNTv5bVPLj1XT0CzKg6K4xhvr1qPR7/wJoOrPeadb689xChETTlQQx9gOKAPPvLeR44lR/MLBVTHOfpTrqBrW5eJx++U4bB4BHvXW654rt1uZbnTbRFu5U2GVkHygjsPWuMw0sqmWRd0pPU9DnnNACv80m+RmO7/ADmkdw0LIEGcjDjt7UXSeVO8e4/Jkbgf88Vb1VIomtrS2O4RRAySgYLseSfp0oAoZzjpjpgUoXPQY+tTNDIiq5TaDxk96afu4ZcUANX5l2njbzn1p0QQhgc4wMN2BpBs8xgWwR2pUO5SuAKAL2m2D6pr2madCA5uruKL5B1G4EkD6A19yzSfZXEEUgWOJVRR6AACvlv9njRzqvxNtr11P2bSLd7lyRwHI2L/AOhMfwr6i/s6K8/0gybvM+bOccdqAMkLz0AYdPWlK8cjnPQURkNGGAAHJ+X19KeOq4HH05FADSzQhZFYbomDjA5xnn9M10brG7EEAw3K8g+pFc6i78gqQehB9DWxpMhm0/yyfngYofp2NAHyZ8WfDUnhvxjcxOpFrcuZY2+vX/GuOlcmFI8DYrEoepr6m+O/hI+JPCRv7NA1/YfvOP4lHWvlkOQCQqntkjpQAx8ZU84PJ9qaX54Jz/OnMAJPlHymgNgHaOe5NAF2wF7ZRx6tChFssnl+bt3BG9PrXc6Z4z0S8vrF/HOmzalBAChmRjmP0O0HkV54sjm3Fv5j+Ru3iLPy7vXHrxSR5BxjKn0oA988fa7aeHvB+h6h4RtSdK1AkIQCqIP9r3rjfCHxN1LRrj/iZRfbdMcgPHnDLz1U+1c5qut6jfeBtA0OcH7LazSPBsOTJ14I9s96xneOW0gyWEqIUZSMd+CKAPfJfi14SjEjFdRlYDIiWHG49hmvK/Gvi298Zyhrp1tbWF/9Gs+wX1J/vVzt1azro9pfBWe2nJRmxwGHqe1WIIdPVN0n2q5iKgO0aY8k9yD3oAdo1/f2byWlheyWcV23lT8/IV9x6V6b8NIrXTvFVhY2SpOZdzS7eoAGd+PrXl0y2sl1HBpMtw/mSCPNyBk54B4r6H8HeFtJ8GQxxwMG1aePZNdyH55D3VfQUAcZ408E+IPEXxetNVs4PO0ySaBxcFvlhVGBKn0NdRq/xA8JaX4n1db24nGpfaFtXMaFwFXoc+mTWl4q8UWPgqwa4uZA2oOpNra/xSMf4voK+Yrid5riaecs80ztIx9WY5oA9P8Ajnpy3clt4g0idtQ0eaMLK1s37m3cZwWA7n3rypoJUijlkiKRSEiN243Y64r1T4V6HNf+FPFt5dytF4eu7TyGRW5eZMkED2zXl7s5jSOd5GePgF/4R6AdqAF020kvdVsrOJS0k86RBe/LCvrvT9Lee/WBmKBFG7byABj9a+fvgVpf9o/EKCeUEwafC1yx7BsYX9cV9R6fCEsB5m/zJz5jEHle4oAnKJDD5VqwixwSBySKbeRRX9q0FxEJomX58nBHuKaXVlLR7pTuxjH3TTApVTHFFt8wEEs33R/XrQByuq2zxanb2zuxhly4YHOU/wAa+aPiLqg1Px/qss7ulvFL9mQ/3EXjP6Zr68vbRJbIIJGleAiRSwwVHcflXyf8X9DGi/EXU4hzb3Z+1xMR1VuT+WaAOdk0y8ivPsxhck/6pscSA9CPrT7jRNYswtwdOvYnR1MZ8s7i+eNtVQ0yxiR7giNRhSWywx02ivVfBHxOdNfsm1G/kjsPJET21wuQhH/LQP8A0oA4Hxn4a8TaZZwa34pZ0e/bEazzbp3OB1XqB0rc8EeHf+EUbTvGni9v7OtLeXfa2b/6+59wvUCtXxj4y0B/Ht74htlbWru1jVLFJwRAr/3sd8VwHiTVdY8Yau+p6zcedclSqgcKgH8Kj0oA91+LuizePfDGh614Ud55IWM0Uatgujf+zCvnOVZhfNbhJmvHk8toyCXL5xj61veHPGuv6B9gGkXpWC0JZYX5SQE5w1e3+Ebnw54/uItb02ys7DxXb5ZopUB/eDv7+xoA5/wzqHjr4Y+D3vNU0RLqzadP3TS/PEpB6gdO3WvLvFV9b6l4gu9bsIvs9rcPl7diMqxHIx6Zr0j4l6/49utDurPUbW0sdNkbMkiEeZJg+vavGZVle2V2H3WwWJ+9QBXuX3uWYZLHJFR4kZFOAVU43f0q5Z3TWclw0McTSyxGMGQBtgPUgHvVNAOUzt56E0AWNMtYtQ1GG2uruKzt3OJLiUfKg96iupRLezNI++IMUUr0KjgEe1Wb+xu7EmG9Qoo5APQk+lZx2oQXOB60APEhztxlT1yeB709XyDnk+9RNw21uCOxpyMCQGIUdMt2oA6lPEqf8ISugHSLHzhP5x1EIPOxn7uf0rCLDG9zgLzwMVLFaiIHzpowTlQqsCSa0fB2hP4h8SWemjcEdt8xA6IvJ/PpQB9Gfs9eH/7C+H8mqXUeLrVX80kjkR9FH869YtoI1gQOFDY6VFptnb2+k2ltCV+zwRqF2nAAAritU1bUrnUJ5bKVkti2EG7HA4z+OM0AdNrFoI5ReQYEchxKVGcH+9WcjZ7lhnrnmt60ltbpna1nilikG1ojx/Osu/tjZygYzC33HI6f7J96AK4PY5HfmprG4NrqMb/8spP3cnqPQ/z/ADqvkY+fAHt/OhkViS54xtG7nI9aAN6+NtbTLNcxKUOY9+M4DcHPtXyx8afBZ8J+J3ltI2/su+JkhI6Rt3SvqHT5FvbLyLpQ0kJw4P8AEvY1jeN/DcHiTwnd6bdYkaPLQv3Udjn2H8qAPjUDnAI/GmY4IA+pFX9VsLjSdUurC8jHnQHaQeM+jD2qo4xFFllIwflHUfWgB0YjDf6QsgDDh1HI/wARSsEiIUSB8jOelIDkKGLGMDjHan4VbYYU+czZV+ox6YoAII1AJBKyR/Mjg4Oa09DDTahbwNHHKXkHEpwCTxjPvWZydinGc4HOMVo6B9lFzc3NxqQ0+7sYvtFkGjMguJVIwh9O5/CgD3D4e6ZPa+HdZ0HYkBeRlaC5AZlBHUf41zH/AAqzXbKG4tomE9o8ZCOj45+neuHs/GGrrrMOsfa3Ooy83LOflk46H2/wrtfh78R5rW9uE8QXkrWdw+2JT83lsx4A9qAOc0Pwpf6RqEWrauBaW2lOt1dRspZwoPTA4BPbJrYv/jVq8vio3OnWVu2jmQKllNHukYHjO4dGPtXW/GHwr4n1u20q10OFpYJCTeJG4UO/8JbPUAYqLwd8KNP8PRWWq+Ibt01iKQOq7gIEbPyjJ6npQBynxzleTx7bi4laVFtEeO2PHkbhkrmvO5roStKDFGgkIV9i9AOwr0X41rYz+OpktZFS/kjUXLuCBnHY9MfSvMpQqt5cTBiDgkdD9KANnxT4il1kWNjbQrYaTYRhILWFiAW/ikb1Ymsua6mm+a6IlKjG5hzge9Vpeikdjg8Vp+GtMbW/EOm6ZGrSG6nVGCnnb3P5UAfQXwO8NQ6T4RhugWa+1siSQt/BGOij8Oa9UkP+lkLwIQFVVPWqOkQRWsBS3ASC2jFtAAOnGBV2JCGHCZ6HH+eaAJEBWNmyfmOcDjFNkj37I8ttzkZ6j3omkaLYxwEzgsOo/CnK3PC5yCNy85oALaTE7RsFbeeSO/bJrxf9obw+LvQYNWiANzpMnlOe7Qse/wBDXs/l4ZZASwUdhnmsHxPYQapDeWF3+8tr+3IOR0OMf/XoA+M5myRkgnHB7UsioLVJjNGXZihiwdwx3+lWtf0m48P61d6VeLia3fAz/Ep6NVGTdgbkCjHT1oAr5UE84x7f5xXV+GYrhvCGsXtrp32q6s7qFbWduViLH5h/tZHasrwxa2V7rCQalOILRkbdITjJHQUy/jubSJNOgvzcWYkM2y1LbFY9C3HWgDsYdD0GT4bare3X2OPxQshaG3t5921QfmBTovGema4/w/qd7pd3HcWlw1sg+aRlGM47H61mIjWt0zAbXGQxHPX1pZ7qSS3SJvuhi3HFAH0Pol7a/FTR7eJrg2up2gPmR9RInfj14rx7xl4YvdBvnjnsZ4bNpD5cjDKt6c9BWJoGtaloWoxz6VcNBMjh89Aw9D7V9MaL4s03xL4TbUNWkjFlEv8ApAlGU8z0X3oA+arHRbzUNUs7OC0mb7RKqjapJwT1z2r3rVfB/gt5bifWoXs7TTnWzct8qu49G71gaj4+0DTr9b/w/MQVURrbKmA+PUnpTYfFs/xEh1uxays5Ly3t/tFjpznK3DDqO2W7470AUPjH4biZhq8F9b7Jl/dRP/DEBwF7GvJNJvptLv4b21SB5ojmNZ0Drn1wa9O8AWmt+OPEtvovirRJptHiVg+YWh+y4B+6x/LHNdJ8QPh1pHhvwhqmqW1rFI1swCEtllQnAyM0AeM+IdXvvEeqvf6o0P2uUBCYYhGvHTgVnzqxmEMcWfKGCyj7x9TTGbeo28KTng9KltpQokSUsARkEHoaAJJIxEu4NgMO/c17V8ENHuLTwzd6nMp8zUXAgB+8I17g+9eT+E9Am8TeILTSYM/vDmV/7kfcn0r6rgigs7W3sbGHbHbxiJQBwAOKAL9hc/ZfD6WMbkTyufNcnBAPYe9ZkkRDkK80ajgKr4Aq7GVAG0hlUkZPrVaWb942GyPx/wAKANQRwliwGGHRxwc1fj1FvKMN/mW1YYLkfOnufWqS8pg8cUqttIAGT14FAE13bm1kRS3mI3Mb9mH+NMAA/wBmn2dzHEhtrpTJZynr3iJ7+w/lT721kssbz5kZOElA/IEUARxSPa3CTxAkrwyf31PUV0lq0U0CvBhoXXKntg9q5k8NnBHqDU9hff2dKFfJtXOW5/1Z9celAHk/xf8AC8euaOdYsIgdQsshwo5lQdR9R1rwWNhlXjU7uo9jX2Dcwmx1OTYVeyuz5sLqePpXhfxc8EnTLyfXdJTfYStuuY0GPJb1GOxoA81nBWQktuJIJx0zTlZ7eQm3f5yNpY84B64qPO7JGAD0owuzLH6CgB8cclxcQwRAvNIwRVA5bnFMkUh3RxteNsHA6EULI9vcCRN6SryrL8pX3FMBY5Z3ZmJySTkk+pNAE/mNNIWfaWY9AP1wKkmdUhiiP/HxC2VI6A9as+HtTOi61balHCkjwHKpIAy7jwCQetVdYuJ59dvLq8RVuJpPMcKu0BiB0A6UAdJB4/8AF1rZraNq04h527gN3PvTLTx7ra3QOq3DapZNgTWk/Rh7EdG9DXKkSS53noOrHmlhTOCAQCe9AHQeNZbaXXVudL1AX2nXMQmhRjmS2H/PN8/xCub45IyD3qT5VLfKC3fFOjQMvZf50ARIVAbOQeozXsfwD8NL5134kvt0YCmGyUj7xP33H06fhXmPhvRLrxJr9tpVkCzSt+9k7Rxjqxr6bsbSOzsYbKwQrbwoIYwDxtH+PWgDsbVljtbZUYbGBkOf4s9KvQkP0RCOpbOMVzNjdyR26RPNH8uQodN2PbNWri6uJI9kk2VJwEVQq/pQBcfUIlkKW8YlYHHmSfdP4UQ6qqMrSwBU5yYzwD9Kykddrc8L26CnBx82QwyePTpQB0hk3W6yxOJE5IZeKwtfJFhHJKrfurgN1wWz1qCNpR/x7XL2/J3bT1/A1DOJJ4mSeaSY9mPJFAHmfxr8Kf23ov8AbNhCG1Ox++ij5poPX3IrwAPvKcjngE9q+vGj8mfKhmQDJL9PcfSvnX4p+EpPDWttdW0R/se9bzIXAyEY9UNAHFN951wGPrjitfT9YtNN8NX9jbWkjahe7Q9xvAWNQewx1rFyFbk8Z6Cp1Fs0TSzh0APEanJf/AUARQLJMHS23HODK54H1JqxrOmPo+oPY3UsZnQBiyHKkEcEGmalftdQLawIttYKcpAvc+rHqT9ary+ZcSSSuxZlwoXqcdqAFRJBbyTIjuN4jyFzknoBXsl7p0mh/BrQYbm3Vp5Lh7m4QHG0noG/CqHgn7P4a+GWqak9vaXviOOYTW9lKfmiQ8CQr36mm3ninUvFfwc1N9TgVZ9Nu0Bkjj2B0bnp65zQB5jKTNcuUhVWkYttUfypLZpIZ0ngkeG5iYPG8bYKEe9RK/lSbt21l5BAqL5mbJyCe9AHpV98YfEtz4b/ALNS42zYCm7Thz/9f3rgrfUboXTyXN7dSrKpEvmSs4bPqCcVVRkUssqk8dj0NQvvOeMigBzJ5bspO1eo9CKUjJVRlpGIVFAyWJ6DFSSzloo0cZVBhRjnntXuHwc+HUmlPH4j8UQp57KPsFmw3FM8+Yw9fQUAdB8KfBb+ENDa5v4Sdd1ABn7iFOyfX1rt2QwQxxKN0khwG9T3qwu8l55/vHnr0psIeVjKwY7htQHsO9AD2RUQICNnv61nuJJXLwwyuh6MiEg1q29lLfTFVOy0TiWYnG1R1Uev9KSfxNdQSmLTbKI2aYWItkEgd+tAC7sDknjoMU4ZHDEdf4c1BE6tGrKR5Z68d/apBkggE/XNAEmQdwPA6Fau2l4hgNhfO3kyDakp7HspP8qoKW2YO4gDB70BQyFCMgjBBHAH+PvQBPJHNBMba4+aUcq3QSD1+tRyY8s704Jxj3qxBcQywLZ6huMH/LKfPzIfc9vrS3Nhc2y7yBNEORIg5x7j/CgCpaOVtnsZkDQZzGehjPt7VW2wSxSQTxgxnh48ZB/D0qy6rIOHGD0Yc1A8ZlOcnzV4LrxQB4b8SvhpcaSs+s+H91zpzNvkt0XLQg9x6ivObC6S3nSc28F2ADhJh8uexx3r63DyQN+8jDIfvNjOfqK8+8c/CzT9eje/8M7LDUz8zQdIZj6f7J96APFdU1i61axsra9itme0LbZ0jCyOp/hZh1A7VnCNkh3uFO7IUZ5HvV7XtH1Tw5dPbazYyWkrDhmGVYezDg1RL7wmTkAADbQBa0myt7u9iXUbyOytFOZZmUs2BzhQOpOK6P4m6jo+v6la6p4eT7PCkK20kMi7HYrwHP1GPyrlFxtBZckMOM9qfNJuXaowFYsufQ9qAGtbTeUriIvG5wHUZBNPuLae3ggklTCzqWQE4JA70ltOsBb5yA6n5Q2K6Pwt4K1rxMsU1nA0Nj0+0znan4Z6/hQByzxYGTjGOxrY8MeHNV8T3XkaVDhAPmuJeIkH1r0rw/8ACqztd83im5F4R922tiRGAO7N1r0WwxDax2ekWyW1rGoCRxcKB/nvQBkeCfC+n+DdNeIFZ7ub/XXB+9If7q+i11lt5RhU7V8yT5lHUIvp9arixSJBLNmSYchDyBSRGXzC9sgeRGB5GFx3FAG/a6e9yhku1lijcfKFX5j7n0pt1pxhgLQXgeLPzb8blH171pQ6zbSuElZreQgHbIMD/vrpVqecqiOgEseMsQMgj1GOtAHItPGJmR2wyfKQf4vepE2M/DLnv82K2Gs9IvH3tZRl++QAcetRRWmk27jyNNV2Q4zgEj86AH6dpwliElwWkGchF+VfqT3qa90lJWEluyRSgYCAfI31qwZ1MBuLiVYIM4GflwPSs2614ZdNOheaTjMso2xj39TQBz93JhHglkHnhijw7vuMPSsnV9Pt9SsJtN1SEXFnKMMp6r7j3FaFxYSNO7rMJbkne7E4JJp8hVoo/ODI47n+tAHzZ448C6h4Yka4iDXmkFvkuUGSg9HHY+9ciCNu8EED9a+wHgVmaFPLjdl5RvuOPx4rzfxv8KItYuTeaO8el3bAboNn7iQ+oxnaaAPBWXcd24Ak9KnYSW0qo0DxyDks2Qf/ANVbXiDwhrugSlNQ06faM4mhUyI3vlc4/GsOS5L3RlnlLSju5waAIJi7SCQli4OVcdV/GtqHxLrMOi3Gmf2hJJZ3Q2yQyHcD7iqWnNblpZZ1inUgp5ZOOT0YfSoEjUjc/QHHy9qAFtBFHcg3gcqoPyDjJ7fhUDb1Zt3KseWPOR6U8RmR8uT15NMLq21UJZ88BRk/kKAGsAdygAe39KajmRkWJGeRztVFGWY+gFdt4T+GPiTxM6y/ZjptgT811eDZx/sqeT+Ve5+DPh94d8GFJ7G3bUNWA/4/7nB2n1Vei0Ach8L/AIUppRtdc8WxrLqI/eW2mNyqejSe/tXrB3STm5uHBcDG0D5QP8acWzumbLNnktyc+1OKlxl3BJH3fT8PWgBhAdQTxGTwuOT7Vq2OjyXAD3e6C3A4U8OR7/3RVXSpobG4lklBnkUbYwuMKe/XvUt5e3N7xL+7hP8AyxQ/e/3j/SgA1W9jmT7JZrtsI+DsGBIfQe1YMmN7YLKPTnitBipHykbc46dKzJ8ec/7tm565oAfEzWkpjlDqw+8jL0HqK0YXWQZjIZT1OcYr5+8B/Fe40+CHTPFiSajpi8R3IObi3Hpn+JfY17VpFzbanapqGiXkepWJ6SQkZT2deuaANrp1Oe2M4FKMjAO8HsT39qqRXium47Q2cHPGKmjZXXer5A5yTQBOMspDfdPBB9at2GoyWOVOZbXOdn8Uf09R7VR5x94Y6YpwBBBOGI7j0oA2rjT7bUAbixmVXPJx90/UdjWNdRS2swF0hjJ4z1R/oaEDwyiS3doX6lkPB+o71rW+qw3MXk6nCFB43Yyjf4UAZAAPG4Y9OeKgmgJy8TMjeq9D9avXMcMVxttZfMiPIPXHtmoyueOvt7UAULhJbm3e31CG2vrbGCJEBGPSuY1T4ceFL9xK+jtbP/ELOTYD+BzXYPE37vyZQOf4hwRUiR4JVSxx8xPTFAHAw/CrwnErL9lvnLngtLyB6dKLf4YeFLUk/YLi4fnaJ5uDXfMFB5ZlYjjnOaR0XhWAJHAyOhoAwtH8KaLpayfYNGsYJJfvSMu/H0zWvFaRKiKcMFPyqPlVcegqYbo0JGGPoKbbyGaFXIUHJBwOlABJbw7iREuT154PtUd1cfZ4tsSoJCdqhB096cbYHP8ApEuPSj7JDjJGGP8AGW5+tAEGnq8iEyEkBiPmHLH/AAq4ZSG+TcyDkqO1M+zgLsibYG4YjnJqdR2QALjPvQBHJ5ggPyCTIwEbvUaPPZFZdPuBb7uTA+WjY/0qzxkk4A5wSMnNN2gqO5HPSgC/Zyw6hcjJ+zXu395DnO8eqnuKn1i5tNMtBPcLubgRxg/NI1c5fQ4mEsQKumDE6thg1M8u8m1FZtSXzpRHhDIAAv8Au44oAtec99tuLvE04bIT+CMew/rT5GkK5Y856gYxT9qh/lUKMZOB1NMV1dmVcjy+Ax/i70ARhCu98qxJ64xUV2TNbyIE8xlXr0FWizcEDP1GKFZigyAF9MUAYrSP5aeYrbBgByK0IwoVhFcBiDkK3arPQgYTAGMdsVGIYlbev3v7wHWgBhBKkyfxcEAAj9ap3Oi6ZdE/adOs5WP8TwAj9K0mUFvm57/Wo2do87ivJwFweaAMmbw3oc0UMEmiaZ5MbbkAiKnP1rmNQ+EfhO9uJJ1tr21eRizCKb5QT2Ax0r0A78Yz25XpijBAACllx97PB/CgDz2z+EPhC2mDSWt5d/7M02B+grrNI0HSdDYro+kWFqxwDIse5sfjWsB8uCCqgdc0Akgl22jsPWgCOQuxHmzFiOzdKai5DYwR1wvSpHV+A20gHPTrQ3BywKkdxQBGFCM0mOp5J9aeWO7duI9wtG4dfXjBpRzxwwJ55oAztNKfariMSFsngHua0SBzy7ZHUmsq+tD5okgUIOScHmlS4eMGPz9yjkLty1AF91yhIGR0PYVlTPEJGGYxjtv/APrVYu47g263E8sVtBgsZJ32Lj1I61wd54+8GWl1JBLrqvJGcMY7csufY55oA+dk6Vo6LrepeHb37Zot5NaTjqY2wG/3h0P40UUAfUfw21Wbxf4UF/qkcKXeCGkt02bj6kcjP4VoWGWlZHYsAcZoooAvwSsZXjPQYwe9TXLGGJ3Xkg4wenWiigCRFDRueBgZ4FVnmdW2jGAAaKKAJtgWXavCkdAKVGbzNm44x60UUAOkYo/FIWwgYAAk4NFFADXkKsoGMGn5wvGKKKAHBAFBHrSBFVvlAGQScDrRRQAjD5AfQE0jZHcnOOtFFAEqLuY8kZz0pkxKAHJJMgU5PaiigCYJjbgkZ4pI4QxOWbOM5FFFAFGBvMuGLqCYiSpq5fNmLLc4xjNFFAEb26fJL827j+I1FcEqAVOAONvaiigCQAFm4xj0J9KZFIzHB6L0oooAkKhQxA5BFN6g/nRRQAsny5YdaRVB+bvnrRRQAD15/M0uNxOT05oooAYSVIA/lTloooAVkCjjP3sUxx8xA7dKKKAI5Ts24Vfm56VSvLh4gQmBjJ6UUUAM8PRnWbkJdyyKrHB8sgfzzXCfGfx7q3gm9aw8PxWUOU/4+Hh8yX8ycfpRRQB4FrfiPWNfuo21jUrq6L8kO5x+Q4FYUku12VUjABwBiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computerized tomography (CT)&nbsp;of the chest in a patient with cystic fibrosis demonstrates mild cylindrical bronchiectasis, with thickened bronchial walls involving the upper lobes and the superior segments of the lower lobes. Note the subsegmental atelectasis in the posterior segment of the right upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cylindrical bronchiectasis in the right middle lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple circular lucencies (arrow) are seen in the contracted middle lobe, most likely as part of a so-called right middle lobe syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16313=[""].join("\n");
var outline_f15_59_16313=null;
var title_f15_59_16314="Coronary reperfusion for acute myocardial infarction in older adults";
var content_f15_59_16314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary reperfusion for acute myocardial infarction in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16314/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/59/16314/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/59/16314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of coronary reperfusion in patients with an acute myocardial infarction (MI) varies with the type of infarction: ST elevation (Q wave) MI (STEMI); or non-ST elevation (non-Q wave) MI (NSTEMI). This topic will review the benefits and potential risks associated with coronary reperfusion after acute MI in older adults. Almost all of the available data come from subset analyses of major trials (in which approximately 10 to 15 percent of patients are over age 75) and nonrandomized retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reperfusion with percutaneous coronary intervention (PCI) or fibrinolytic agents improves outcomes in patients with symptoms suggestive of an acute myocardial infarction (MI) who have ST segment elevation, new or presumably new left bundle branch block that obscures ST segment analysis, or a true posterior MI. Primary PCI, usually consisting of angioplasty with stenting, has become a particularly attractive strategy in elderly patients without shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an acute non-ST elevation (non-Q) wave MI (NSTEMI) pose different issues. Fibrinolysis in these patients increases the risk of intracranial hemorrhage and does not appear to improve cardiac outcomes at least in part because the infarct-related artery is not occluded in 60 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of \"primary PCI\" performed within two hours in NSTEMI is also uncertain as the major trials that compared this modality to fibrinolysis involved patients who were eligible for fibrinolysis (ie, with an STEMI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this limitation, most patients with an NSTEMI undergo early catheterization and, if appropriate, revascularization within 4 to 48 hours. The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of a non-ST elevation acute coronary syndrome (ACS) and the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guidelines on percutaneous coronary intervention (as well as the 2007 focused update) recommended an early invasive strategy to ST segment depression, elevated cardiac enzymes, and a number of other factors in patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Early invasive strategy in NSTEMI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRIMARY PCI IN STEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary percutaneous coronary intervention (PCI) overcomes a number of limitations of fibrinolysis. The limitations include the attainment of vessel opening in only 80 percent of patients, the restoration of normal (TIMI grade 3) flow in only 50 to 60 percent, an appreciable risk of early recurrent ischemia (threatened reocclusion), thrombotic coronary reocclusion, reinfarction even after apparently successful fibrinolysis, and the avoidance of intracranial hemorrhage.",
"   </p>",
"   <p>",
"    Controlled trials in younger patients with an acute STEMI who are eligible for either pharmacologic or mechanical reperfusion have shown that primary PCI produces better outcomes than fibrinolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data on the efficacy of primary PCI in older adults mostly consist of subset analyses of major trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and nonrandomized retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The randomized GUSTO IIb angioplasty substudy of 1138 patients (mean age 63, 314 patients &ge;70 years of age) found that better outcomes with PCI compared to fibrinolytic therapy were seen in all age groups, with the largest reduction in the primary end point of 30 day death or reinfarction seen in patients between the ages of 70 and 79 (10.1 versus 18.1 percent). This benefit was entirely due to a reduction in 30 day mortality (5 versus 14.3 percent).",
"     </li>",
"     <li>",
"      In a meta-analysis of ten randomized trials comparing primary angioplasty to fibrinolysis in 2635 patients (43 percent from GUSTO IIb), primary angioplasty produced the greatest reduction in mortality in patients over 70 years of age (9.2 versus 18.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Medicare review of 37,983 patients &ge;65 years of age who presented with an ST elevation MI within 12 hours of symptom onset; 38 percent received a fibrinolytic agent and 4 percent underwent primary PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/12\">",
"       12",
"      </a>",
"      ]. Compared to patients undergoing no reperfusion, the patients treated with fibrinolytic therapy had significantly fewer comorbidities (eg, less hypertension, diabetes, heart failure, prior MI or stroke).",
"      <br/>",
"      <br/>",
"      After adjusting for demographic, clinical, hospital and physician factors, and cointerventions, 30 day survival was significantly improved with primary PCI (odds ratio 0.79 compared to no reperfusion) but not with fibrinolytic therapy. At one year, both modalities were associated with a significant survival advantage (odds ratio 0.71 and 0.84, respectively). The effect was fibrinolysis was significant for those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      , but not streptokinase at least up to age 85.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fibrinolytic therapy was associated with a significant increase in intracranial hemorrhage compared to those receiving no reperfusion (1.5 versus 0.1 percent). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Risk of intracranial hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar findings were noted in another Medicare analysis from the Cooperative Cardiovascular Project [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/13\">",
"       13",
"      </a>",
"      ]. The 2.5 percent of elderly patients who underwent primary PCI had, when compared to the 23 percent treated with fibrinolytic therapy, significant reductions in mortality at 30 days and one year (8.7 versus 11.9 percent and 14.4 versus 17.6 percent, respectively) (",
"      <a class=\"graphic graphic_figure graphicRef57303 \" href=\"UTD.htm?2/19/2366\">",
"       figure 1",
"      </a>",
"      ). However, the benefit at one year was no longer significant among patients classified as ideal for reperfusion therapy.",
"     </li>",
"     <li>",
"      A separate issue, the advantage of PCI with stenting compared to percutaneous transluminal coronary angioplasty (PTCA), has been demonstrated in a number of trials. In a subset analysis from the CADILLAC trial, the rate of the primary end point at six months was significantly reduced with stenting in patients &ge;65 years of age (12.9 versus 20.5 percent with PTCA, odds ratio 0.58); a similar magnitude of benefit was noted in younger patients (9.2 versus 16.6 percent, odds ratio 0.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/10\">",
"       10",
"      </a>",
"      ]. The benefit in older adults was entirely due to a lower rate of target vessel revascularization with stenting (7.0 versus 17.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of mortality, reinfarction, disabling stroke, or major bleeding were independent of perfusion modality. Not surprisingly, the one-year mortality rate increased with age: 2.1 percent for age 55 to 65 years; 7.1 percent for 65 to 75 years of age, and 11.1 percent for age &gt;75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one small controlled trial has directly compared PCI with fibrinolysis in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/17\">",
"     17",
"    </a>",
"    ]. In this study, 87 patients over age 75 with an acute STEMI presenting with six hours of symptom onset (or within 6 to 24 hours if there was ongoing ischemia) were randomly assigned to primary PCI (with or without stenting) or intravenous streptokinase. Primary PCI was associated with a significantly lower incidence of the combined end point of death, reinfarction, or stroke at both 30 days (9 versus 29 percent with streptokinase) and one year (13 versus 44 percent). The one year benefit was entirely due to a reduction in mortality (11 versus 29 percent).",
"   </p>",
"   <p>",
"    Despite the benefit of primary PCI compared to fibrinolysis in older adults, the adverse effect of increasing age on outcome does not vary with the treatment strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. In the GUSTO-IIb angioplasty substudy, for example, the outcome was better with PCI than with fibrinolysis for each age group. However, irrespective of treatment, the mortality risk increased with age; after adjusting for baseline characteristics, each increment of 10 years of age increased the 30-day risk of death or reinfarction by 1.32. The success rate may be lower in patients over age 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, elderly patients undergoing",
"    <span class=\"nowrap\">",
"     rescue/adjunctive",
"    </span>",
"    PCI following fibrinolytic therapy have worse outcomes compared to younger patients. In an analysis of 1472 patients treated with",
"    <span class=\"nowrap\">",
"     rescue/adjunctive",
"    </span>",
"    PCI following fibrinolytic therapy in the TIMI trials, elderly patients had slower flow in the infarct-related artery after PCI and a four-fold greater mortality at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clopidogrel before primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials specifically evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with an STEMI who are treated with primary PCI. However, most clinicians extrapolate from randomized trials in patients with a non-ST elevation ACS (PCI-CURE and CREDO), which showed that clopidogrel improves both short-term and long-term cardiovascular outcomes when given in addition to aspirin in patients treated with PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on older adults are limited, although the mean age in these trials was 62 years. Subgroup analysis from PCI-CURE revealed an almost significant trend toward benefit in patients &ge;65 years of age (relative risk 0.79 compared to placebo, 95% CI 0.57-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and ACCP guidelines, which gave a class I recommendation to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in all patients treated with primary PCI with stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. Data from CREDO suggested that, to reduce acute thrombotic complications, a 300 mg loading dose of clopidogrel must be given at least six hours and probably at least 15 hours before PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/24\">",
"     24",
"    </a>",
"    ]. However, primary PCI should be performed within 90 minutes of presentation to the hospital.",
"   </p>",
"   <p>",
"    Due in part to this time limitation, we suggest a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose of 600 mg followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Compared to the 300 mg loading dose, the 600 mg loading dose appears to produce maximal antiplatelet activity within two to three hours, to have a greater antiplatelet effect, to diminish the likelihood of clopidogrel resistance, and may, based upon limited data, improve outcomes. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GP IIb/IIIa inhibitors before primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of major randomized trials showed a survival benefit from the administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor before primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/25\">",
"     25",
"    </a>",
"    ]. Limited data from a subgroup analysis in one of these trials found that the benefit was at least as great in patients &ge;65 years of age as in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H25#H25\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Use in primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary PCI has become the reperfusion method of choice in qualified centers in appropriate elderly patients because of better cardiac outcomes and avoidance of the risk of intracranial hemorrhage associated with fibrinolytic therapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Risk of intracranial hemorrhage'",
"    </a>",
"    below.) The recommended door-to-balloon time is less than 90 minutes or, in patients who present within three hours of symptom onset, an expected door-to-balloon time minus an expected door-to-needle time of &le;60 minutes&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the potential benefits of primary PCI, when patient transfer is required for primary PCI, the guideline recommendations regarding door-to-balloon times are met in only 4 to 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC THERAPY IN STEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated by the above observations, primary PCI is the preferred reperfusion strategy in elderly patients with an STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/28\">",
"     28",
"    </a>",
"    ]. Fibrinolytic therapy is an alternative in patients with an STEMI in whom primary PCI is not available or cannot be performed promptly. There are, however, concerns about benefit from fibrinolysis in the very old and the risks of intracranial hemorrhage and left ventricular free wall rupture.",
"   </p>",
"   <p>",
"    As with primary PCI, the available data on the efficacy of fibrinolytic therapy in older adults primarily consists of subset analyses of major trials or nonrandomized retrospective analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated a consistent benefit from fibrinolytic therapy in eligible elderly patients with an acute STEMI up to age 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/18,29,30\">",
"     18,29,30",
"    </a>",
"    ]. However, the absolute mortality rate increases markedly with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/18,29,30\">",
"     18,29,30",
"    </a>",
"    ], similar to that described above for primary PCI and not explainable by larger infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/31\">",
"     31",
"    </a>",
"    ], and there are conflicting data on the efficacy of fibrinolytic therapy in patients over age 75 (",
"    <a class=\"graphic graphic_figure graphicRef68512 \" href=\"UTD.htm?30/27/31166\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A beneficial effect was noted in a pooled analysis of 28,896 patients treated with streptokinase for acute MI in the GISSI-1 and ISIS-2 trials. The following findings were noted in the subset of patients over age 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality was significantly reduced by fibrinolysis (24.9 versus 28.8 percent with placebo). This 3.9 percent absolute mortality reduction was significantly larger than the 2.4 percent absolute mortality reduction observed in younger patients (8.3 versus 10.7 percent).",
"     </li>",
"     <li>",
"      The mortality in treated elderly patients was higher than in treated patients under age 75 (25 versus 8.3 percent). This is similar to the increased mortality with age noted above in patients who undergo primary PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings were different in a report from the Fibrinolytic Therapy Trialists that reviewed nine randomized trials of 58,600 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/30\">",
"     30",
"    </a>",
"    ]. The absolute 35-day mortality benefit from fibrinolytic therapy was 1.7 percent in patients between the ages of 55 to 64 (7.2 versus 8.9 percent with placebo) and 2.7 percent in patients between the ages of 65 and 74 (13.5 versus 16.1 percent). However, patients &ge;75 years of age had only a nonsignificant 1.0 percent reduction in 35-day mortality (24.3 versus 25.3 percent with placebo).",
"   </p>",
"   <p>",
"    The benefit from fibrinolysis in older adults has been less consistent in reports that evaluated nationwide practice rather than clinical trials. This may be due at least in part to the fact that patients enrolled in trials are usually healthier and receive more consistent medical therapy.",
"   </p>",
"   <p>",
"    A study cited above evaluated 37,983 Medicare patients &ge;65 years of age who presented with an STEMI within 12 hours of symptom onset; 38 percent received a fibrinolytic agent and 4 percent underwent primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/12\">",
"     12",
"    </a>",
"    ]. After adjusting for demographic, clinical hospital and physician factors, and cointerventions, there was no difference in the 30 day survival with fibrinolysis compared to no therapy. In contrast, 30 day survival was significantly improved with primary PCI (odds ratio 0.79). However, at one year, both fibrinolytic therapy and primary PCI were associated with a significant survival advantage (odds ratio 0.84 and 0.71, respectively).",
"   </p>",
"   <p>",
"    In another Medicare review, a survival benefit at 30 days with fibrinolytic therapy was noted in patients between the ages of 65 and 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/32\">",
"     32",
"    </a>",
"    ]. However, among patients between the ages of 76 and 86, fibrinolysis was associated with a significant survival",
"    <strong>",
"     disadvantage",
"    </strong>",
"    at 30 days (hazard ratio for mortality 1.31) (",
"    <a class=\"graphic graphic_figure graphicRef68512 \" href=\"UTD.htm?30/27/31166\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In summary, a number of studies have questioned whether there is a significant short-term (30 to 35 day) mortality benefit from fibrinolytic therapy in patients &ge;75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/12,30,32,33\">",
"     12,30,32,33",
"    </a>",
"    ]. However, long-term mortality appears to be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/12\">",
"     12",
"    </a>",
"    ]. The possible lack of benefit in these patients may, as described below, be due at least in part to increases in left ventricular free wall rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ] and to a lesser degree intracranial hemorrhage.",
"   </p>",
"   <p>",
"    The Fibrinolytic Therapy Trialists report concluded that the data do not provide evidence for withholding fibrinolytic therapy on the basis of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/30\">",
"     30",
"    </a>",
"    ]. Similarly, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of STEMI and the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update did not recommend an age limitation to fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23,35\">",
"     23,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Time to fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earlier reperfusion occurs, the greater the degree of myocardial salvage that can be achieved. The benefit is greatest when fibrinolytic agents are administered within the first four hours after the onset of symptoms, particularly within the first",
"    <strong>",
"     two hours",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 3",
"    </a>",
"    ). It has been estimated that an approximate 1 percent reduction in mortality occurs for each hour of time saved within the first six hours.",
"   </p>",
"   <p>",
"    Based upon these findings, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended, in the absence of a contraindication or primary PCI, administering fibrinolytic therapy to patients who present up to 12 hours after symptom onset and have ST elevation in at least two contiguous or adjacent leads, new or presumably new left bundle branch block, or a true posterior MI&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. The guidelines also concluded that it is reasonable to administer fibrinolytic therapy to patients presenting 12 to 24 hours after the onset of symptoms if they have continuing symptoms and persistent ST segment elevation on the ECG. The time from presentation to drug administration should be less than",
"    <strong>",
"     30 minutes",
"    </strong>",
"    . No changes to this approach were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these recommendations, there is often a delay in the administration of fibrinolytic therapy to elderly patients. In a review of 17,379 patients &ge;65 years of age, only 22 percent received fibrinolysis within 30 minutes of hospital arrival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/36\">",
"     36",
"    </a>",
"    ]. After adjusting for clinical characteristics, a delay in therapy beyond 30 and 90 minutes was associated with an increase in one-year mortality rates of 9 and 27 percent, respectively, compared to treatment within 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Choice of fibrinolytic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GUSTO-1 trial showed an absolute 1 percent mortality benefit (15 percent risk reduction) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) compared to streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/37\">",
"     37",
"    </a>",
"    ]. A similar benefit was noted in older adults. Of the 41,021 patients in this study, 12 percent were older than 75 years and 4 percent were older than 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/18\">",
"     18",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not surprisingly, there was a progressive increase in in-hospital and 30 day mortality as age increased from 65 to 74, 75 to 84, and &ge;85.",
"     </li>",
"     <li>",
"      For patients under age 85, the combined end point of death or disabling stroke occurred less often with accelerated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      compared to streptokinase and, at one year, accelerated alteplase was associated with a lower mortality. Because only 412 patients (1 percent of the total) were &ge;85 years of age, the superiority of any particular regimen could not be determined in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we prefer the more fibrin-specific",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    because it is associated with a lower frequency of noncerebral bleeding, as shown in the ASSENT-2 trial, and it is easier to administer, requiring only a single bolus (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/38\">",
"     38",
"    </a>",
"    ]. Among females over age 75 who weigh less than 67 kg, tenecteplase also may be associated with a lower rate of intracranial hemorrhage (1.1 versus 3.0 percent with alteplase) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H20#H20\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'ASSENT-2 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large randomized trials &mdash; CLARITY-TIMI 28 and",
"    <span class=\"nowrap\">",
"     COMMIT/CCS-2",
"    </span>",
"    &mdash; showed significant benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy at presentation in patients treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In subgroup analysis, benefit was seen in patients between the ages of 65 and 75 in CLARITY-TIMI 28 (there were no patients over age 75 in this trial) and over age 70 in",
"    <span class=\"nowrap\">",
"     COMMIT/CCS-2.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With fibrinolytic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended regimen in patients &le;75 years of age is that used in CLARITY-TIMI 28: a 300 mg loading dose followed by 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/40\">",
"     40",
"    </a>",
"    ]. In comparison, the optimal initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    dose is uncertain in patients over age 75. Some suggest that a 300 mg loading dose could be considered in patients with a low estimated risk of intracranial hemorrhage (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 2",
"    </a>",
"    ); however, others suggest beginning with a 75 mg dose, which was used in all patients in",
"    <span class=\"nowrap\">",
"     COMMIT/CCS-2,",
"    </span>",
"    since the safety of a 300 mg loading dose (ie, freedom from intracranial hemorrhage) has not been established in this age group. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Risk of intracranial hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of benefit in randomized trials from the combination of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors with half-dose fibrinolytic therapy in patients with an STEMI. Such regimens are not recommended in major guidelines, particularly in patients over the age of 75 who would have an increased risk of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H32#H32\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Use with a fibrinolytic agent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H23#H23\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'GP IIb/IIIa inhibitors and reduced dose fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk of intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH) after fibrinolytic therapy is usually a devastating complication as 53 to 60 percent die during hospitalization and as many as 25 percent of survivors have a disabling residual neurologic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69243091#H69243091\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is often reluctance to administer fibrinolytic agents to eligible elderly patients due in part to the increased risk of ICH with age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. This may be related in part to a persistent fibrinolytic state after bolus fibrinolytic therapy that is more pronounced in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absolute risk was addressed in a retrospective analysis from the Cooperative Cardiovascular Project of 31,732 Medicare patients &ge;65 years of age (mean age 73 years) who received fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/44\">",
"     44",
"    </a>",
"    ]. The rate of ICH was 1.43 percent. Independent predictors for this complication were age &ge;75 years, female sex, black race, prior stroke, blood pressure &ge;160 mmHg, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (versus other fibrinolytic agents), excessive anticoagulation (INR = 4), and lower body weight (&le;65 kg for women and &lt;80 kg for men).",
"   </p>",
"   <p>",
"    The incidence of ICH was associated with the number of risk factors present (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No or one factor &mdash; 0.7 percent",
"     </li>",
"     <li>",
"      Two factors &mdash; 1 percent",
"     </li>",
"     <li>",
"      Three factors &mdash; 1.6 percent",
"     </li>",
"     <li>",
"      Four factors &mdash; 2.5 percent",
"     </li>",
"     <li>",
"      Five or more factors &mdash; 4.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the available data suggest that the risk of ICH progressively increases over age 70 and particularly over age 75 (eg, 2.1 versus 1.1 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    alone over age 75 in the GUSTO V trial) treated with the combination of a fibrin-specific fibrinolytic agent and a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/1,46,47\">",
"     1,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H23#H23\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'GP IIb/IIIa inhibitors and reduced dose fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force gave a class I recommendation to the use of primary PCI rather than fibrinolysis in patients with a risk of ICH &ge;4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. No changes to this approach were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk of free wall rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of left ventricular free wall rupture appears to be substantially increased in patients with an acute STEMI &ge;75 years of age who are treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the left ventricular free wall'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of this effect was illustrated in a review of 706 consecutive patients &ge;75 years of age with a first STEMI who were treated with primary PCI, fibrinolytic therapy, or no reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/33\">",
"     33",
"    </a>",
"    ]. The patients who received fibrinolytic therapy had a significantly greater likelihood of free wall rupture (17.1 versus 7.9 and 4.9 percent in those with no reperfusion and primary PCI, respectively, adjusted relative risk 3.62 compared to no reperfusion). Free wall rupture accounted for 54 percent of deaths after fibrinolytic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraindications to fibrinolytic therapy in older adults are similar to those in younger patients (",
"    <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H25#H25\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Underutilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the benefit of fibrinolytic therapy in elderly patients, at least below age 76, marked underutilization is common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This problem was illustrated in a national registry review of over 350,000 patients published in 1996, which found the following age-related frequency of fibrinolytic use in patients with an acute STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &le;65 &mdash; 51 percent",
"     </li>",
"     <li>",
"      Age 65 to 74 &mdash; 19 percent",
"     </li>",
"     <li>",
"      Age &gt;75 &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients presenting within six hours of the onset of symptoms who were 75 to 84 or &ge;85 years of age were 56 and 81 percent less likely to received fibrinolytic therapy than younger subjects.",
"   </p>",
"   <p>",
"    Multiple factors contribute to the decreased utilization of fibrinolytic therapy in older adults. In addition to a general concern about bleeding complications and a greater likelihood of having relative or absolute contraindications to fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/50\">",
"     50",
"    </a>",
"    ], older patients are more likely to have atypical symptoms and to present later than six hours after the onset of symptoms, and are less likely to have an electrocardiogram diagnostic for an acute STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/29,50-52\">",
"     29,50-52",
"    </a>",
"    ]. In a series of over 3000 Medicare patients, for example, only 34 percent of eligible elderly patients with an acute STEMI and no contraindications received fibrinolytic therapy; however, the frequency was 75 percent in the subset presenting with chest pain and within six hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the underutilization of fibrinolytic agents in older adults generally reflects clinical judgment rather than inadvertent omission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EARLY INVASIVE STRATEGY IN NSTEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with an NSTEMI undergo early catheterization and, if appropriate, revascularization within 4 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The minority of patients deemed to be at low risk (eg, TIMI risk score 0 to 2) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) can be treated with either an early invasive or conservative approach. By definition, elderly patients with an NSTEMI (ie, elevated cardiac enzymes) have a TIMI risk score of at least 2 and, if there is ST segment depression, at least 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data that are available suggest that selected elderly patients derive a greater benefit from an early invasive strategy than younger patients, although with an increased risk of bleeding complications. This was suggested by an analysis from TACTICS-TIMI 18 in which patients presenting with unstable angina or an NSTEMI were randomly assigned to an invasive strategy (catheterization within 4 to 48 hours and revascularization with PCI or CABG if feasible) or conservative medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link&amp;anchor=H8#H8\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'TACTICS-TIMI 18 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the 2220 trial participants, 962 (43 percent) were &ge;65 years of age. Elderly patients were more likely to have a TIMI risk score &ge;3 than younger patients (91 versus 63 percent) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). In an analysis by age, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients &ge;65 years of age, an early invasive strategy compared to a conservative strategy significantly reduced the incidence of death or MI at 30 days (5.7 versus 9.8 percent) and six months (8.8 versus 13.6 percent). In contrast, the benefit of an invasive strategy was not significant for younger patients at 30 days (3.9 versus 4.9 percent) or six months (6.1 versus 6.5 percent).",
"     </li>",
"     <li>",
"      Among patients &gt;75 years of age, the advantage of an early invasive strategy in reducing the incidence of death or MI at six months was even more marked (10.8 versus 21.6 percent).",
"     </li>",
"     <li>",
"      Among patients &gt;75 years of age, an early invasive strategy significantly increased the frequency of major bleeding during the index hospitalization (16.6 versus 6.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of this analysis is that the study excluded patients with major comorbidities, including a history of stroke, renal dysfunction, bleeding disorder, or clinically important systemic disease. Patients with severe heart failure, cardiogenic shock, or secondary angina were also excluded. As a result, the findings may not be applicable to some higher-risk elderly patients.",
"   </p>",
"   <p>",
"    Similar findings were noted in a predefined analysis from the FRISC II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/55\">",
"     55",
"    </a>",
"    ]. The incidence of death",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MI at six months was significantly reduced with an invasive strategy in patients &ge;65 years of age (10.5 versus 15.8 percent, risk ratio 0.66) but not in younger patients (8.1 percent in both groups).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clopidogrel before PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of patients undergoing PCI for NSTEMI (PCI-CURE and CREDO) have shown significant benefit from pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Data on older adults are limited, although the mean age in these trials was 62 years. Subgroup analysis from PCI-CURE revealed an almost significant trend toward benefit in patients &ge;65 years of age (relative risk 0.79 compared to placebo, 95% CI 0.57-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a 300 mg loading dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to reduce acute thrombotic complications, it appears that it must be given at least 15 hours before PCI (",
"    <a class=\"graphic graphic_figure graphicRef79395 \" href=\"UTD.htm?32/47/33533\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/24\">",
"     24",
"    </a>",
"    ]. Due in part to this time limitation, we suggest a loading dose of 600 mg unless PCI will not be performed for at least 24 hours, followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Compared to the 300 mg loading dose, the 600 mg loading dose appears to produce maximal antiplatelet activity within two to three hours, to have a greater antiplatelet effect, to diminish the likelihood of clopidogrel resistance, and may, based upon limited data, improve outcomes. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H14#H14\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     GP IIb/IIIa inhibitors before PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized controlled trials evaluating the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in non-ST elevation acute coronary syndromes concluded that patients with an NSTEMI benefit from therapy when they undergo PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/56\">",
"     56",
"    </a>",
"    ]. The mean age was 64 and, in subgroup analysis, age did not appear to preclude benefit.",
"   </p>",
"   <p>",
"    Based in part upon these observations, the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on PCI recommended that a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor should be given to patients with an NSTEMI in whom PCI is going to be done or is planned [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/8\">",
"     8",
"    </a>",
"    ]. The GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor infusion should be initiated at presentation and continued for 48 to 72 hours or until PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CARDIOGENIC SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the role of coronary revascularization in elderly patients with cardiogenic shock. Coronary revascularization is preferred to fibrinolysis, because of limited efficacy of the latter approach. In animal studies, dissolution of a coronary artery thrombus by fibrinolytic therapy is markedly depressed when hypotension is present. However, fibrinolytic therapy may be of some benefit when used in combination with an intraaortic balloon pump to maintain coronary perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Reperfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of revascularization was illustrated in the SHOCK trial in which 302 patients with an acute MI and shock due to left ventricular dysfunction were randomly assigned to initial medical therapy or to revascularization with PCI or coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/57\">",
"     57",
"    </a>",
"    ]. There was a significant mortality benefit with emergency revascularization that, on subgroup analysis, was only apparent in patients under 75 years of age. However, only 56 patients aged 75 or older were enrolled in the trial, and no definitive recommendations could be made for this age group based upon the trial results alone.",
"   </p>",
"   <p>",
"    The results were different in an analysis from the much larger nonrandomized SHOCK registry that included 277 patients &ge;75 years of age and 588 younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/58\">",
"     58",
"    </a>",
"    ]. Fewer older patients were treated with early revascularization due to comorbidities. After exclusion of early deaths and adjustment for covariates, the relative risk for in-hospital mortality was significantly reduced with early revascularization compared to initial medical therapy with or without late revascularization in both older (relative risk 0.46) and younger patients (relative risk 0.76).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are consistent with those made in the 2007 AHA scientific statement on acute coronary care in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. This statement advises caution in the extrapolation of conclusions regarding the benefits and risks of reperfusion therapy in the management of STEMI in patients older than 85 years of age due to insufficient data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding findings in older adults, although not definitive, suggest a benefit of primary PCI compared to fibrinolysis, which is similar to the benefit observed in younger patients. Many qualified centers prefer primary PCI in appropriate elderly patients because of the avoidance of intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/28\">",
"     28",
"    </a>",
"    ]. In particular, primary PCI should be performed in patients who have a contraindication to fibrinolysis but are eligible for reperfusion&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not well studied in acute MI, drug-eluting stents are being utilized with increasing frequency in preference to bare metal stents whenever feasible because they are associated with a marked reduction in the incidence of restenosis and target vessel revascularization. Although data are limited in older adults, the mean age of patients in two of the major drug-eluting stent trials was 62&plusmn;11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ]. A loading dose of 600 mg is recommended followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clopidogrel before primary PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All patients should also be treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. We suggest that a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor be given as early as possible before PCI as long as the administration of such therapy does not delay transfer to the catheterization laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H25#H25\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Use in primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fibrinolysis in STEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolysis is an alternative if primary PCI is not available or cannot be performed within two hours of presentation. As noted above, there is some concern of lack of benefit and perhaps even worse outcomes in patients over the age of 75 (",
"    <a class=\"graphic graphic_figure graphicRef68512 \" href=\"UTD.htm?30/27/31166\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. An increase in left ventricular free wall rupture may limit the benefit in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Fibrinolytic therapy in STEMI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and Fibrinolytic Therapy Trialists Collaborative Group concluded that age alone should not affect the decision to administer fibrinolytic therapy in eligible patients without a contraindication (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23,30\">",
"     23,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines which recommended, in the absence of a contraindication or primary PCI, administering fibrinolytic therapy (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ) to patients who present up to 12 hours after symptom onset and have ST elevation in at least two contiguous or adjacent leads, new or presumably new left bundle branch block, or a true posterior MI&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines also concluded that it is reasonable to administer fibrinolytic therapy to patients presenting 12 to 24 hours after the onset of symptoms if they have continuing symptoms and persistent ST segment elevation on the ECG. The time from presentation to drug administration should be less than",
"    <strong>",
"     30 minutes",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Patients who are to be treated with fibrinolytic therapy should be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The recommended regimen in patients &le;75 years of age is that used in CLARITY-TIMI 28: a 300 mg loading dose followed by 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/40\">",
"     40",
"    </a>",
"    ]. In comparison, the optimal initial clopidogrel dose is uncertain in patients over age 75. Some suggest that a 300 mg loading dose could be considered in patients with a low estimated risk of intracranial hemorrhage (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 2",
"    </a>",
"    ); however, others suggest beginning with a 75 mg dose, which was used in all patients in",
"    <span class=\"nowrap\">",
"     COMMIT/CCS-2,",
"    </span>",
"    since the safety of a 300 mg loading dose (ie, freedom from intracranial hemorrhage) has not been established in this age group. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Clopidogrel'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On the other hand, administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor is not recommended because of apparent lack of efficacy and, in patients over age 75, an increased risk of ICH. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'GP IIb/IIIa inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with an NSTEMI undergo early catheterization and, if appropriate, revascularization within 4 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/7\">",
"     7",
"    </a>",
"    ]. The minority of patients deemed to be at low risk (eg, TIMI risk score 0 to 2) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) can be treated with either an early invasive or conservative approach. By definition, elderly patients with an NSTEMI (ie, elevated cardiac enzymes) have a TIMI risk score of at least 2 and, if there is ST segment depression, at least 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials of patients undergoing PCI for NSTEMI have shown significant benefit from pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. A loading dose of 600 mg is recommended followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Clopidogrel before PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on PCI and the 2004 ACCP Consensus Conference recommend that a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor be given to patients with an NSTEMI who undergo PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/8\">",
"     8",
"    </a>",
"    ]. The GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor infusion should be initiated at presentation and continued for 48 to 72 hours or until PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early revascularization, which is the preferred therapy for cardiogenic shock due to left ventricular dysfunction complicating an acute MI in patients under age 75, also appears to be beneficial in appropriately selected patients &ge;75 years of age. The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines gave a class IIa recommendation (the weight of evidence is in favor of efficacy) to primary PCI or emergent CABG in selected patients in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/59/16314/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/1\">",
"      Mehta RH, Granger CB, Alexander KP, et al. Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol 2005; 45:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/2\">",
"      Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/3\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/4\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/5\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/6\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/9\">",
"      Taus L, Gerzov&aacute; J. Personality of semen donors and their social behaviour. Czech Med 1991; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/10\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/11\">",
"      Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004; 110:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/12\">",
"      Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000; 36:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/13\">",
"      Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999; 282:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/14\">",
"      Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998; 31:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/15\">",
"      Mehta RH, Sadiq I, Goldberg RJ, et al. Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2004; 147:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/16\">",
"      Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (&lt;2 h), intermediate (2-4 h) and late (&gt;4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/17\">",
"      de Boer MJ, Ottervanger JP, van 't Hof AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002; 39:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/18\">",
"      White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996; 94:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/19\">",
"      Singh M, Mathew V, Garratt KN, et al. Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am J Med 2000; 108:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/20\">",
"      Kirtane AJ, Skolnick AH, Pinto DS, et al. Angiographic and Clinical Outcomes Following Rescue Angioplasty for ST-Elevation Myocardial Infarction in the Elderly. Am J Geriatr Cardiol 2005; 2:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/21\">",
"      Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/22\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/24\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/25\">",
"      De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/26\">",
"      Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/27\">",
"      Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/28\">",
"      Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/29\">",
"      Collins, R. Optimizing thrombolytic therapy of acute myocardial infarction: Age is not a contraindication. Circulation 1991; 84:II230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/30\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/31\">",
"      Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med 1993; 329:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/32\">",
"      Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/33\">",
"      Bueno H, Mart&iacute;nez-Sell&eacute;s M, P&eacute;rez-David E, L&oacute;pez-Palop R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur Heart J 2005; 26:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/34\">",
"      Keeley EC, de Lemos JA. Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the ageing heart. Eur Heart J 2005; 26:1693.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/36\">",
"      Berger AK, Radford MJ, Krumholz HM. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the cooperative cardiovascular project. Am Heart J 2000; 139:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/37\">",
"      Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/38\">",
"      Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/39\">",
"      Van de Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/40\">",
"      Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179.",
"     </a>",
"    </li>",
"    <li>",
"     www.commit-ccs2.org (Accessed on March 24, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/42\">",
"      Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/43\">",
"      Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/44\">",
"      Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/45\">",
"      Stangl K, Laule M, Tenckhoff B, et al. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction. Am J Cardiol 1998; 81:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/46\">",
"      Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/47\">",
"      Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003; 24:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/48\">",
"      Gurwitz JH, Gore JM, Goldberg RJ, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med 1996; 124:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/49\">",
"      Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group. J Am Coll Cardiol 1991; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/50\">",
"      Krumholz HM, Murillo JE, Chen J, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 1997; 277:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/51\">",
"      Nadelmann J, Frishman WH, Ooi WL, et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990; 66:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/52\">",
"      Krumholz HM, Friesinger GC, Cook EF, et al. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc 1994; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/53\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/54\">",
"      Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/55\">",
"      Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/56\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/57\">",
"      Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/58\">",
"      Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003; 24:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/59\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/59/16314/abstract/60\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 51 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16314=[""].join("\n");
var outline_f15_59_16314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRIMARY PCI IN STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clopidogrel before primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GP IIb/IIIa inhibitors before primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FIBRINOLYTIC THERAPY IN STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Time to fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Choice of fibrinolytic agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk of intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk of free wall rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Underutilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EARLY INVASIVE STRATEGY IN NSTEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clopidogrel before PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GP IIb/IIIa inhibitors before PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CARDIOGENIC SHOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fibrinolysis in STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/51\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/51|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/19/2366\" title=\"figure 1\">",
"      Mortality after MI lower in elderly with PTCA vs fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/27/31166\" title=\"figure 2\">",
"      Thrombolytic therapy in elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 3\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/47/33533\" title=\"figure 4\">",
"      Clopidogrel timing before PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/51|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/33/26140\" title=\"table 1\">",
"      Thrombolytic regimens STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/52/43851\" title=\"table 2\">",
"      Risk factors for intracranial hemorrhage with thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23820\" title=\"table 3\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_59_16315="Minimum medication need asthma";
var content_f15_59_16315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimum medication need in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Occasional bronchodilator, not daily and/or occasional",
"cromolyn, not daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Daily bronchodilator and/or daily cromolyn and/or daily",
"low-dose inhaled steroid (&lt;800&nbsp;&micro;g beclomethasone or",
"equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Bronchodilator on demand and daily high-dose inhaled",
"steroid (&gt;800&nbsp;&micro;g beclomethasone or equivalent) or",
"occasional course (1-3/yr) systemic steroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Bronchodilator on demand and daily high-dose inhaled",
"steroid (&gt;1000 &micro;g beclomethasone or equivalent) and",
"daily systemic steroid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16315=[""].join("\n");
var outline_f15_59_16315=null;
var title_f15_59_16316="Less com pathogens after BMT-II";
var content_f15_59_16316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immediate postengraftment (3 weeks to 3 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Enteroviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Coxsackie A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Echovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rotavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BK virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leishmania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptosporidia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strongyloides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasmodium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardia intestinalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microsporidia spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        M. tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Atypical mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. avium complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. fortuitum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        M. chelonae",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16316=[""].join("\n");
var outline_f15_59_16316=null;
var title_f15_59_16317="Biologic rx to xenotransplant";
var content_f15_59_16317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Schematic representation of the biological responses to organ xenotransplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 160px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic showing the different possible responses to organ xenotransplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Platt, JL. Nature 1998; 392:11.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16317=[""].join("\n");
var outline_f15_59_16317=null;
var title_f15_59_16318="Acne medications 2";
var content_f15_59_16318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acne medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Partial list of preparations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Select adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical retinoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tretinoin",
"       </td>",
"       <td>",
"        Once daily, at bedtime",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Creams:",
"         </strong>",
"         0.025%, 0.0375%, 0.05%, 0.1%",
"        </p>",
"        <p>",
"         <strong>",
"          Polyolprepolymer-2 cream:",
"         </strong>",
"         0.025%",
"        </p>",
"        <p>",
"         <strong>",
"          Gels:",
"         </strong>",
"         0.01%, 0.025%, 0.05%",
"        </p>",
"        <p>",
"         <strong>",
"          Microsphere gels:",
"         </strong>",
"         0.04%, 0.1%",
"        </p>",
"        <p>",
"         <strong>",
"          Polyolprepolymer-2 gel:",
"         </strong>",
"         0.025%",
"        </p>",
"       </td>",
"       <td>",
"        Local skin irritation, dryness, and flaking; sun sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adapalene",
"       </td>",
"       <td>",
"        Once daily, at bedtime",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Cream:",
"         </strong>",
"         0.1%",
"        </p>",
"        <p>",
"         <strong>",
"          Gels:",
"         </strong>",
"         0.1%, 0.3%",
"        </p>",
"        <p>",
"         <strong>",
"          Lotion:",
"         </strong>",
"         0.1%",
"        </p>",
"       </td>",
"       <td>",
"        Local skin irritation, dryness, and flaking; sun sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tazarotene",
"       </td>",
"       <td>",
"        Once daily, at bedtime",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Creams:",
"         </strong>",
"         0.05%, 0.1%",
"        </p>",
"        <p>",
"         <strong>",
"          Gels:",
"         </strong>",
"         0.05%, 0.1%",
"        </p>",
"       </td>",
"       <td>",
"        Pregnancy category X; local skin irritation, dryness, and flaking; sun sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzoyl peroxide",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Multiple 2.5 to 10% gels, lotions, creams, pads, masks, cleansers",
"       </td>",
"       <td>",
"        Local skin irritation; may bleach hair or clothing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"       </td>",
"       <td>",
"        <p>",
"         Twice daily",
"        </p>",
"        <p>",
"         Once daily (foam)",
"        </p>",
"       </td>",
"       <td>",
"        1% gel, lotion, pledget, solution, foam",
"       </td>",
"       <td>",
"        Rare risk of pseudomembranous colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        2% gel, solution, pledget",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dapsone",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        5% gel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfacetamide",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        10% lotion, wash, suspension, pad plus 10% urea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical combination products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzoyl peroxide 5 percent/",
"        <br/>",
"        Clindamycin 1 percent",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Local skin irritation; may bleach hair or clothing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzoyl peroxide 2.5 percent/",
"        <br/>",
"        Clindamycin 1.2 percent",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Locak skin irritation; may bleach hair or clothing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzoyl peroxide 5 percent/",
"        <br/>",
"        Erythromycin 3 percent",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Local skin irritation; may bleach hair or clothing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin 1.2 percent/",
"        <br/>",
"        Tretinoin 0.025 percent",
"       </td>",
"       <td>",
"        Once daily, at bedtime",
"       </td>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Local skin irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzoyl peroxide 2.5 percent/",
"        <br/>",
"        Adapalene 0.1 percent",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Local skin irritation; may bleach hair or clothing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Azelaic acid",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        20% cream, 15% gel",
"       </td>",
"       <td>",
"        Local skin irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Oral antibiotics*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tetracycline",
"       </td>",
"       <td>",
"        500 mg twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Photosensitivity, gastrointestinal distress; contraindicated in pregnancy and young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        50 to 100 mg twice daily or 150 mg once daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Photosensitivity, gastrointestinal distress; contraindicated in pregnancy and young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minocycline",
"       </td>",
"       <td>",
"        50 to 100 mg twice daily",
"        <strong>",
"         or",
"        </strong>",
"        1 mg/kd/day of extended release formulation (round to nearest available strength: 45, 65, 90 or 135 mg tablets)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Dizziness, drug-induced lupus, skin discoloration; contraindicated in pregnancy and young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin",
"       </td>",
"       <td>",
"        500 mg twice daily (base)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Gastrointestinal distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        160 mg/800 mg once to twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, toxic epidermal necrolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin",
"       </td>",
"       <td>",
"        Intermittent dosing due to long drug half-life; optimum regimen unknown",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Gastrointestinal distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hormonal agents*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Combination oral contraceptives (estrogen/progestin)",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Nausea, breast tenderness, weight gain, thromboembolic events; see topic entitled \"Risks and side-effects associated with estrogen-progestin contraceptives\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spironolactone",
"       </td>",
"       <td>",
"        25 to 200 mg/day in one or two equally divided doses; doses of 50 to 100 mg/day may be as effective as higher doses and reduce side effects",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Contraindicated in pregnancy; menstrual irregularity, breast tenderness, minor gastrointestinal symptoms, orthostatic hypotension, hyperkalemia, dizziness, headaches, fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Oral retinoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral isotretinoin",
"       </td>",
"       <td>",
"        0.5 mg/kg/day, increasing to 1 mg/kg/day in one or two equally divided doses; total dose 120 to 150 mg/kg over 20 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Teratogenicity (absolutely contraindicated in pregnancy), mucocutaneous effects, hypertriglyceridemia, others; see topic entitled \"Oral isotretinoin therapy for acne vulgaris\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      * Usual oral dose for adult or adolescent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16318=[""].join("\n");
var outline_f15_59_16318=null;
var title_f15_59_16319="Color flow Doppler main PA";
var content_f15_59_16319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler color flow of the main pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A short axis cut through the cardiac base demonstrates the long axis projection of the main pulmonary artery (MPA). The Doppler flow information is color encoded so that flow in all parts of the artery can be displayed. In this systolic frame, flow should be entirely toward the transducer, or blue in color; however, much of the color shown is red hued, indicating that flow exceeds 0.48 m/sec. This color change indicates aliasing, not reversed flow.",
"    <div class=\"footnotes\">",
"     RVOT: right ventricular outflow tract; Ao: aorta; RA: right atrium; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_59_16319=[""].join("\n");
var outline_f15_59_16319=null;
